<?xml version="1.0" encoding="UTF-8"?><!-- Normalized for easier text mining. --><xocs:doc xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.elsevier.com/xml/ja/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://schema.elsevier.com/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta><xocs:content-family>serial</xocs:content-family><xocs:content-type>JL</xocs:content-type><xocs:cid>276216</xocs:cid><xocs:srctitle>Stem Cell Research</xocs:srctitle><xocs:normalized-srctitle>STEMCELLRESEARCH</xocs:normalized-srctitle><xocs:orig-load-date>2014-01-27</xocs:orig-load-date><xocs:ew-transaction-id>2014-03-11T08:56:38</xocs:ew-transaction-id><xocs:eid>1-s2.0-S1873506114000075</xocs:eid><xocs:pii-formatted>S1873-5061(14)00007-5</xocs:pii-formatted><xocs:pii-unformatted>S1873506114000075</xocs:pii-unformatted><xocs:doi>10.1016/j.scr.2014.01.004</xocs:doi><xocs:item-stage>S300</xocs:item-stage><xocs:item-version-number>S300.2</xocs:item-version-number><xocs:item-weight>FULL-TEXT</xocs:item-weight><xocs:hub-eid>1-s2.0-S1873506113X00078</xocs:hub-eid><xocs:timestamp>2014-03-11T12:13:04.936676-04:00</xocs:timestamp><xocs:issns><xocs:issn-primary-formatted>1873-5061</xocs:issn-primary-formatted><xocs:issn-primary-unformatted>18735061</xocs:issn-primary-unformatted></xocs:issns><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>NONE</xocs:funding-body-id><xocs:crossmark>false</xocs:crossmark><xocs:vol-first>12</xocs:vol-first><xocs:iss-first>2</xocs:iss-first><xocs:vol-iss-suppl-text>Volume 12, Issue 2</xocs:vol-iss-suppl-text><xocs:sort-order>21</xocs:sort-order><xocs:first-fp>574</xocs:first-fp><xocs:last-lp>583</xocs:last-lp><xocs:pages><xocs:first-page>574</xocs:first-page><xocs:last-page>583</xocs:last-page></xocs:pages><xocs:cover-date-orig><xocs:start-date>201403</xocs:start-date></xocs:cover-date-orig><xocs:cover-date-text>March 2014</xocs:cover-date-text><xocs:cover-date-start>2014-03-01</xocs:cover-date-start><xocs:cover-date-end>2014-03-31</xocs:cover-date-end><xocs:cover-date-year>2014</xocs:cover-date-year><xocs:hub-sec><xocs:hub-sec-title>Regular Articles</xocs:hub-sec-title></xocs:hub-sec><xocs:document-type>article</xocs:document-type><xocs:document-subtype>fla</xocs:document-subtype><xocs:copyright-line>Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.</xocs:copyright-line><xocs:normalized-article-title>GENERATIONFAMILIALAMYLOIDOTICPOLYNEUROPATHYSPECIFICINDUCEDPLURIPOTENTSTEMCELLS</xocs:normalized-article-title><xocs:normalized-first-auth-surname>ISONO</xocs:normalized-first-auth-surname><xocs:normalized-first-auth-initial>K</xocs:normalized-first-auth-initial><xocs:item-toc><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Materials and methods</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Reagents</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Patients</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Generation of iPS cells</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Differentiation into hepatocyte-like cells</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>ALP staining</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Reverse-transcription polymerase chain reaction (RT-PCR) analysis</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Real-time PCR analysis</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Immunocytochemistry</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>PAS analysis</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Albumin secretion assay</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>PCR-restriction fragment length polymorphism analysis (PCR-RFLP)</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS)</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Liquid chromatography-tandem mass spectrometry (LC-MS/MS)</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Western blotting</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Enzyme-Linked ImmunoSorbent Assay (ELISA)</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Results</xocs:item-toc-section-title><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Generation of iPS cells from patients with FAP</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Differentiation of FAP-specific iPS cells into hepatocyte-like cells</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Production of wild-type TTR and ATTR Val30Met by differentiated hepatocyte-like cells</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Discussion</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:sections"><xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:acknowledgment"><xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title></xocs:item-toc-entry><xocs:item-toc-entry ref-elem="ce:bibliography"><xocs:item-toc-section-title>References</xocs:item-toc-section-title></xocs:item-toc-entry></xocs:item-toc><xocs:references><xocs:ref-info refid="rf0005"><xocs:ref-normalized-surname>ANDO</xocs:ref-normalized-surname><xocs:ref-pub-year>1998</xocs:ref-pub-year><xocs:ref-first-fp>288</xocs:ref-first-fp><xocs:ref-last-lp>300</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0010"><xocs:ref-normalized-surname>ANDO</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>2312</xocs:ref-first-fp><xocs:ref-last-lp>2323</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0015"><xocs:ref-normalized-surname>ANDO</xocs:ref-normalized-surname><xocs:ref-pub-year>1993</xocs:ref-pub-year><xocs:ref-first-fp>920</xocs:ref-first-fp><xocs:ref-last-lp>922</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0020"><xocs:ref-normalized-surname>ANDO</xocs:ref-normalized-surname><xocs:ref-pub-year>1995</xocs:ref-pub-year><xocs:ref-first-fp>354</xocs:ref-first-fp><xocs:ref-last-lp>358</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0025"><xocs:ref-normalized-surname>ANDO</xocs:ref-normalized-surname><xocs:ref-pub-year>1995</xocs:ref-pub-year><xocs:ref-first-fp>195</xocs:ref-first-fp><xocs:ref-last-lp>196</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0030"><xocs:ref-normalized-surname>ANDO</xocs:ref-normalized-surname><xocs:ref-pub-year>1997</xocs:ref-pub-year><xocs:ref-first-fp>295</xocs:ref-first-fp><xocs:ref-last-lp>298</xocs:ref-last-lp><xocs:ref-normalized-initial>E</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0035"><xocs:ref-normalized-surname>ANDO</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>1057</xocs:ref-first-fp><xocs:ref-last-lp>1062</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0040"><xocs:ref-normalized-surname>ARAKI</xocs:ref-normalized-surname><xocs:ref-pub-year>1984</xocs:ref-pub-year><xocs:ref-first-fp>128</xocs:ref-first-fp><xocs:ref-last-lp>133</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0045"><xocs:ref-normalized-surname>BAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>14234</xocs:ref-first-fp><xocs:ref-last-lp>14239</xocs:ref-last-lp><xocs:ref-normalized-initial>H</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0050"><xocs:ref-normalized-surname>BENSON</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>411</xocs:ref-first-fp><xocs:ref-last-lp>423</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0055"><xocs:ref-normalized-surname>BERG</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>127</xocs:ref-first-fp><xocs:ref-last-lp>138</xocs:ref-last-lp><xocs:ref-normalized-initial>I</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0060"><xocs:ref-normalized-surname>BUXBAUM</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>3095</xocs:ref-first-fp><xocs:ref-last-lp>3101</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0065"><xocs:ref-normalized-surname>BUXBAUM</xocs:ref-normalized-surname><xocs:ref-pub-year>2003</xocs:ref-pub-year><xocs:ref-first-fp>2</xocs:ref-first-fp><xocs:ref-last-lp>6</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0070"><xocs:ref-normalized-surname>CARDOSO</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>37</xocs:ref-first-fp><xocs:ref-last-lp>47</xocs:ref-last-lp><xocs:ref-normalized-initial>I</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0075"><xocs:ref-normalized-surname>DIMOS</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>1218</xocs:ref-first-fp><xocs:ref-last-lp>1221</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0080"><xocs:ref-normalized-surname>EBERT</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>277</xocs:ref-first-fp><xocs:ref-last-lp>280</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0085"><xocs:ref-normalized-surname>FUSAKI</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>348</xocs:ref-first-fp><xocs:ref-last-lp>362</xocs:ref-last-lp><xocs:ref-normalized-initial>N</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0090"><xocs:ref-normalized-surname>GORE</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>63</xocs:ref-first-fp><xocs:ref-last-lp>67</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0095"><xocs:ref-normalized-surname>HAMMARSTROM</xocs:ref-normalized-surname><xocs:ref-pub-year>2003</xocs:ref-pub-year><xocs:ref-first-fp>6656</xocs:ref-first-fp><xocs:ref-last-lp>6663</xocs:ref-last-lp><xocs:ref-normalized-initial>P</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0100"><xocs:ref-normalized-surname>HARUI</xocs:ref-normalized-surname><xocs:ref-pub-year>1999</xocs:ref-pub-year><xocs:ref-first-fp>6141</xocs:ref-first-fp><xocs:ref-last-lp>6146</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0105"><xocs:ref-normalized-surname>HUSSEIN</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>58</xocs:ref-first-fp><xocs:ref-last-lp>62</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0110"><xocs:ref-normalized-surname>JIA</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>197</xocs:ref-first-fp><xocs:ref-last-lp>199</xocs:ref-last-lp><xocs:ref-normalized-initial>F</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0115"><xocs:ref-normalized-surname>KANAI</xocs:ref-normalized-surname><xocs:ref-pub-year>1968</xocs:ref-pub-year><xocs:ref-first-fp>2025</xocs:ref-first-fp><xocs:ref-last-lp>2044</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0120"><xocs:ref-normalized-surname>KATOMOTOZAKI</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>133</xocs:ref-first-fp><xocs:ref-last-lp>140</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0125"><xocs:ref-normalized-surname>KAWAJI</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>306</xocs:ref-first-fp><xocs:ref-last-lp>312</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0130"><xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname><xocs:ref-pub-year>2000</xocs:ref-pub-year><xocs:ref-first-fp>6564</xocs:ref-first-fp><xocs:ref-last-lp>6569</xocs:ref-last-lp><xocs:ref-normalized-initial>H</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0135"><xocs:ref-normalized-surname>MAEHR</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>15768</xocs:ref-first-fp><xocs:ref-last-lp>15773</xocs:ref-last-lp><xocs:ref-normalized-initial>R</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0140"><xocs:ref-normalized-surname>OKITA</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>949</xocs:ref-first-fp><xocs:ref-last-lp>953</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0145"><xocs:ref-normalized-surname>ONG</xocs:ref-normalized-surname><xocs:ref-pub-year>1994</xocs:ref-pub-year><xocs:ref-first-fp>1835</xocs:ref-first-fp><xocs:ref-last-lp>1842</xocs:ref-last-lp><xocs:ref-normalized-initial>D</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0150"><xocs:ref-normalized-surname>POKRZYWA</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>913</xocs:ref-first-fp><xocs:ref-last-lp>924</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0155"><xocs:ref-normalized-surname>RAYA</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>53</xocs:ref-first-fp><xocs:ref-last-lp>59</xocs:ref-last-lp><xocs:ref-normalized-initial>A</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0160"><xocs:ref-normalized-surname>SAHA</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>584</xocs:ref-first-fp><xocs:ref-last-lp>595</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0165"><xocs:ref-normalized-surname>SARAIVA</xocs:ref-normalized-surname><xocs:ref-pub-year>1983</xocs:ref-pub-year><xocs:ref-first-fp>261</xocs:ref-first-fp><xocs:ref-last-lp>270</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0170"><xocs:ref-normalized-surname>SATO</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>2501</xocs:ref-first-fp><xocs:ref-last-lp>2512</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0175"><xocs:ref-normalized-surname>SEKIJIMA</xocs:ref-normalized-surname><xocs:ref-pub-year>2003</xocs:ref-pub-year><xocs:ref-first-fp>409</xocs:ref-first-fp><xocs:ref-last-lp>417</xocs:ref-last-lp><xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0180"><xocs:ref-normalized-surname>SHIRAKI</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>731</xocs:ref-first-fp><xocs:ref-last-lp>746</xocs:ref-last-lp><xocs:ref-normalized-initial>N</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0185"><xocs:ref-normalized-surname>SHIRAKI</xocs:ref-normalized-surname><xocs:ref-pub-year>2011</xocs:ref-pub-year><xocs:ref-first-fp>e24228</xocs:ref-first-fp><xocs:ref-normalized-initial>N</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0190"><xocs:ref-normalized-surname>SOLDNER</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>964</xocs:ref-first-fp><xocs:ref-last-lp>977</xocs:ref-last-lp><xocs:ref-normalized-initial>F</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0195"><xocs:ref-normalized-surname>SOUSA</xocs:ref-normalized-surname><xocs:ref-pub-year>2000</xocs:ref-pub-year><xocs:ref-first-fp>1101</xocs:ref-first-fp><xocs:ref-last-lp>1110</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0200"><xocs:ref-normalized-surname>STADTFELD</xocs:ref-normalized-surname><xocs:ref-pub-year>2008</xocs:ref-pub-year><xocs:ref-first-fp>945</xocs:ref-first-fp><xocs:ref-last-lp>949</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0205"><xocs:ref-normalized-surname>SUEYOSHI</xocs:ref-normalized-surname><xocs:ref-pub-year>2012</xocs:ref-pub-year><xocs:ref-first-fp>23</xocs:ref-first-fp><xocs:ref-last-lp>30</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0210"><xocs:ref-normalized-surname>SUHR</xocs:ref-normalized-surname><xocs:ref-pub-year>1995</xocs:ref-pub-year><xocs:ref-first-fp>933</xocs:ref-first-fp><xocs:ref-last-lp>938</xocs:ref-last-lp><xocs:ref-normalized-initial>O</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0215"><xocs:ref-normalized-surname>SULLIVAN</xocs:ref-normalized-surname><xocs:ref-pub-year>2010</xocs:ref-pub-year><xocs:ref-first-fp>329</xocs:ref-first-fp><xocs:ref-last-lp>335</xocs:ref-last-lp><xocs:ref-normalized-initial>G</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0220"><xocs:ref-normalized-surname>TAKAHASHI</xocs:ref-normalized-surname><xocs:ref-pub-year>2006</xocs:ref-pub-year><xocs:ref-first-fp>663</xocs:ref-first-fp><xocs:ref-last-lp>676</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0225"><xocs:ref-normalized-surname>TAKAHASHI</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>861</xocs:ref-first-fp><xocs:ref-last-lp>872</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0230"><xocs:ref-normalized-surname>UEDA</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>1223</xocs:ref-first-fp><xocs:ref-last-lp>1227</xocs:ref-last-lp><xocs:ref-normalized-initial>M</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0235"><xocs:ref-normalized-surname>WESTERMARK</xocs:ref-normalized-surname><xocs:ref-pub-year>2002</xocs:ref-pub-year><xocs:ref-first-fp>197</xocs:ref-first-fp><xocs:ref-last-lp>200</xocs:ref-last-lp><xocs:ref-normalized-initial>P</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0240"><xocs:ref-normalized-surname>WIGMORE</xocs:ref-normalized-surname><xocs:ref-pub-year>1997</xocs:ref-pub-year><xocs:ref-first-fp>103</xocs:ref-first-fp><xocs:ref-last-lp>111</xocs:ref-last-lp><xocs:ref-normalized-initial>S</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0245"><xocs:ref-normalized-surname>WOLTJEN</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>766</xocs:ref-first-fp><xocs:ref-last-lp>770</xocs:ref-last-lp><xocs:ref-normalized-initial>K</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0250"><xocs:ref-normalized-surname>YAMASHITA</xocs:ref-normalized-surname><xocs:ref-pub-year>2005</xocs:ref-pub-year><xocs:ref-first-fp>41</xocs:ref-first-fp><xocs:ref-last-lp>45</xocs:ref-last-lp><xocs:ref-normalized-initial>T</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0255"><xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname><xocs:ref-pub-year>2007</xocs:ref-pub-year><xocs:ref-first-fp>1917</xocs:ref-first-fp><xocs:ref-last-lp>1920</xocs:ref-last-lp><xocs:ref-normalized-initial>J</xocs:ref-normalized-initial></xocs:ref-info><xocs:ref-info refid="rf0260"><xocs:ref-normalized-surname>ZHOU</xocs:ref-normalized-surname><xocs:ref-pub-year>2009</xocs:ref-pub-year><xocs:ref-first-fp>381</xocs:ref-first-fp><xocs:ref-last-lp>384</xocs:ref-last-lp><xocs:ref-normalized-initial>H</xocs:ref-normalized-initial></xocs:ref-info></xocs:references><xocs:attachment-metadata-doc><xocs:attachment-set-type>item</xocs:attachment-set-type><xocs:pii-formatted>S1873-5061(14)00007-5</xocs:pii-formatted><xocs:pii-unformatted>S1873506114000075</xocs:pii-unformatted><xocs:eid>1-s2.0-S1873506114000075</xocs:eid><xocs:doi>10.1016/j.scr.2014.01.004</xocs:doi><xocs:cid>276216</xocs:cid><xocs:timestamp>2014-03-11T12:13:04.936676-04:00</xocs:timestamp><xocs:path>/276216/1-s2.0-S1873506113X00078/1-s2.0-S1873506114000075/</xocs:path><xocs:cover-date-start>2014-03-01</xocs:cover-date-start><xocs:cover-date-end>2014-03-31</xocs:cover-date-end><xocs:sponsored-access-type>UNLIMITED</xocs:sponsored-access-type><xocs:funding-body-id>NONE</xocs:funding-body-id><xocs:attachments><xocs:web-pdf><xocs:attachment-eid>1-s2.0-S1873506114000075-main.pdf</xocs:attachment-eid><xocs:filename>main.pdf</xocs:filename><xocs:extension>pdf</xocs:extension><xocs:pdf-optimized>true</xocs:pdf-optimized><xocs:filesize>1131037</xocs:filesize><xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose><xocs:web-pdf-page-count>10</xocs:web-pdf-page-count><xocs:web-pdf-images><xocs:web-pdf-image><xocs:attachment-eid>1-s2.0-S1873506114000075-main_1.png</xocs:attachment-eid><xocs:filename>main_1.png</xocs:filename><xocs:extension>png</xocs:extension><xocs:filesize>130590</xocs:filesize><xocs:pixel-height>849</xocs:pixel-height><xocs:pixel-width>656</xocs:pixel-width><xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type><xocs:pdf-page-num>1</xocs:pdf-page-num></xocs:web-pdf-image></xocs:web-pdf-images></xocs:web-pdf><xocs:attachment><xocs:attachment-eid>1-s2.0-S1873506114000075-gr5_lrg.jpg</xocs:attachment-eid><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>117489</xocs:filesize><xocs:pixel-height>1055</xocs:pixel-height><xocs:pixel-width>1839</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S1873506114000075-gr4_lrg.jpg</xocs:attachment-eid><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>82149</xocs:filesize><xocs:pixel-height>695</xocs:pixel-height><xocs:pixel-width>1612</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S1873506114000075-gr3_lrg.jpg</xocs:attachment-eid><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>563672</xocs:filesize><xocs:pixel-height>1408</xocs:pixel-height><xocs:pixel-width>1990</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S1873506114000075-gr2_lrg.jpg</xocs:attachment-eid><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>380221</xocs:filesize><xocs:pixel-height>1246</xocs:pixel-height><xocs:pixel-width>1873</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S1873506114000075-gr1_lrg.jpg</xocs:attachment-eid><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1_lrg.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>29340</xocs:filesize><xocs:pixel-height>327</xocs:pixel-height><xocs:pixel-width>931</xocs:pixel-width><xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S1873506114000075-gr5.jpg</xocs:attachment-eid><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>35270</xocs:filesize><xocs:pixel-height>397</xocs:pixel-height><xocs:pixel-width>692</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S1873506114000075-gr4.jpg</xocs:attachment-eid><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>27216</xocs:filesize><xocs:pixel-height>262</xocs:pixel-height><xocs:pixel-width>607</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S1873506114000075-gr3.jpg</xocs:attachment-eid><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>138045</xocs:filesize><xocs:pixel-height>530</xocs:pixel-height><xocs:pixel-width>749</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S1873506114000075-gr2.jpg</xocs:attachment-eid><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>91188</xocs:filesize><xocs:pixel-height>469</xocs:pixel-height><xocs:pixel-width>705</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S1873506114000075-gr1.jpg</xocs:attachment-eid><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.jpg</xocs:filename><xocs:extension>jpg</xocs:extension><xocs:filesize>11146</xocs:filesize><xocs:pixel-height>123</xocs:pixel-height><xocs:pixel-width>350</xocs:pixel-width><xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S1873506114000075-gr5.sml</xocs:attachment-eid><xocs:file-basename>gr5</xocs:file-basename><xocs:filename>gr5.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>2515</xocs:filesize><xocs:pixel-height>126</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S1873506114000075-gr4.sml</xocs:attachment-eid><xocs:file-basename>gr4</xocs:file-basename><xocs:filename>gr4.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>2618</xocs:filesize><xocs:pixel-height>94</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S1873506114000075-gr3.sml</xocs:attachment-eid><xocs:file-basename>gr3</xocs:file-basename><xocs:filename>gr3.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>13665</xocs:filesize><xocs:pixel-height>155</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S1873506114000075-gr2.sml</xocs:attachment-eid><xocs:file-basename>gr2</xocs:file-basename><xocs:filename>gr2.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>10377</xocs:filesize><xocs:pixel-height>146</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment><xocs:attachment><xocs:attachment-eid>1-s2.0-S1873506114000075-gr1.sml</xocs:attachment-eid><xocs:file-basename>gr1</xocs:file-basename><xocs:filename>gr1.sml</xocs:filename><xocs:extension>sml</xocs:extension><xocs:filesize>1563</xocs:filesize><xocs:pixel-height>77</xocs:pixel-height><xocs:pixel-width>219</xocs:pixel-width><xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type></xocs:attachment></xocs:attachments></xocs:attachment-metadata-doc><xocs:refkeys><xocs:refkey3>ISONOX2014X574</xocs:refkey3><xocs:refkey4lp>ISONOX2014X574X583</xocs:refkey4lp><xocs:refkey4ai>ISONOX2014X574XK</xocs:refkey4ai><xocs:refkey5>ISONOX2014X574X583XK</xocs:refkey5></xocs:refkeys><xocs:open-access><xocs:oa-article-status is-open-access="1" is-open-archive="0">Full</xocs:oa-article-status><xocs:oa-access-effective-date>2014-01-22T00:26:59Z</xocs:oa-access-effective-date><xocs:oa-sponsor><xocs:oa-sponsor-type>Author</xocs:oa-sponsor-type></xocs:oa-sponsor><xocs:oa-user-license>http://creativecommons.org/licenses/by/3.0/</xocs:oa-user-license></xocs:open-access></xocs:meta><xocs:serial-item><article xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" version="5.2" docsubtype="fla" xml:lang="en"><item-info><jid>SCR</jid><aid>399</aid><ce:pii>S1873-5061(14)00007-5</ce:pii><ce:doi>10.1016/j.scr.2014.01.004</ce:doi><ce:copyright type="other" year="2014">The Authors</ce:copyright></item-info><ce:floats><ce:figure id="f0005"><ce:label>Figure 1</ce:label><ce:caption id="ca0010"><ce:simple-para id="sp0025" view="all">SELDI-TOF MS analysis of TTR forms in the serum of an FAP patient from whom FAP-specific iPS cells were generated. Peaks at 13,761 and 13,792<ce:hsp sp="0.25"/>Da were free forms of wild-type TTR and ATTR Val30Met, respectively. Arrows indicate the wild-type TTR peaks. Asterisks indicate the ATTR Val30Met peaks.</ce:simple-para></ce:caption><ce:link locator="gr1" id="lk0005"/></ce:figure><ce:figure id="f0010"><ce:label>Figure 2</ce:label><ce:caption id="ca0015"><ce:simple-para id="sp0030" view="all">Efficient generation of FAP-specific iPS cells by SeV vectors. (A) ALP staining of cells growing on 100-mm dishes. (B) RT-PCR analysis of expression of NANOG, TERT, SeV, and β-actin. iPS-1 to iPS-10 are established clones. (C) Typical staining of FAP-specific iPS cell colonies with anti-SeV antibodies. The colony was partially positive (left panel) and negative (right panel) for SeV. BC, bright contrast. Scale bar, 50<ce:hsp sp="0.25"/>μm and 100<ce:hsp sp="0.25"/>μm. (D) Immunostaining of established clones with pluripotency marker Oct3/4 (green). Nuclei were stained with DAPI (blue). BF, bright field. Scale bar, 100<ce:hsp sp="0.25"/>μm.</ce:simple-para></ce:caption><ce:link locator="gr2" id="lk0010"/></ce:figure><ce:figure id="f0015"><ce:label>Figure 3</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0035" view="all">Differentiation of FAP-specific iPS cells. (A) Schematic of the experimental procedure. FAP-specific iPS cells were differentiated on Day (D) 0 to Day 5 in DMEM supplemented with 100<ce:hsp sp="0.25"/>ng/ml Activin and 2% B27 supplement. From D5 to D7, RPMI-1640 supplemented with 10<ce:hsp sp="0.25"/>ng/ml BMP4, 10<ce:hsp sp="0.25"/>ng/ml Fgf10, and 2% B27 supplement were used. At D7, the supplements were changed to 1<ce:hsp sp="0.25"/>μM dexamethasone (Dex) and 10<ce:hsp sp="0.25"/>ng/ml HGF in KSR with DMEM. (B) Quantification via real-time PCR analyses of the relative expression levels of the pluripotency marker Oct3/4, the definitive endoderm marker Sox17, and the hepatic markers AFP and ALB in differentiated FAP-specific iPS cells at D5, D13, and D20 and in undifferentiated iPS cells (Undiff) (<ce:italic>n</ce:italic><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3). The expression levels were normalized to that of GAPDH. RNA from 201B7 which were differentiated into hepatocyte-like cells the same as FAP-specific iPS cells and the hepatic cell line HepG2 were examined as a positive control (<ce:italic>n</ce:italic><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3). (C) Differentiated FAP-specific iPS cells on D5 were stained for Oct3/4 (green) and Sox 17 (purple), D13 were stained for AFP (green) and HNF-4α (purple), D20 were stained for AFP (green) and Albumin (purple). Scale bar, 100<ce:hsp sp="0.25"/>μm. (D) FAP-specific iPS cells differentiated on D5, D13 and D20 were stained for Sox 17 (red), AFP (green) and ALB (red), and counterstained with DAPI (blue). Efficiency of differentiation assessed by dividing the number of positive cells for Sox 17, AFP and ALB by the number of total cells (<ce:italic>n</ce:italic><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3). Scale bar, 100<ce:hsp sp="0.25"/>μm. (E) Albumin secretion by differentiated FAP-specific iPS cells on D20 and undifferentiated iPS cells was measured (<ce:italic>n</ce:italic><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3). The differentiation medium was changed to fresh medium 48<ce:hsp sp="0.25"/>h before the assay. (F) PAS staining of differentiated FAP-specific iPS cells on D20 indicated numerous hepatocyte-like cells within the colonies with cytoplasmic glycogen storage. Scale bar, 100<ce:hsp sp="0.25"/>μm.</ce:simple-para></ce:caption><ce:link locator="gr3" id="lk0015"/></ce:figure><ce:figure id="f0020"><ce:label>Figure 4</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0045" view="all">TTR expression in differentiated FAP-specific iPS cells. (A) Quantification via real-time PCR analyses of the relative expression levels of TTR mRNA in differentiated FAP-specific iPS cells on D5, D13, D20, and 201B7 on D20 and in undifferentiated iPS cells (Undiff) (<ce:italic>n</ce:italic><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3). The expression levels were normalized to that of GAPDH. (B) TTR protein expression determined in the D20 supernatant by Western blotting with anti-TTR polyclonal antibody. (C) TTR secretion by differentiated FAP-specific iPS cells on D20 and undifferentiated iPS cells was measured by ELISA assay (<ce:italic>n</ce:italic><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>3).</ce:simple-para></ce:caption><ce:link locator="gr4" id="lk0020"/></ce:figure><ce:figure id="f0025"><ce:label>Figure 5</ce:label><ce:caption id="ca0030"><ce:simple-para id="sp0050" view="all">TTR and ATTR expression in differentiated FAP-specific iPS cells. (A) PCR-RFLP analysis of TTR and ATTR mRNA expression of differentiated hepatocyte-like cells on D20. Arrows indicate the wild-type TTR peaks. Asterisks indicate the ATTR Val30Met peaks after digestion with the <ce:italic>Nsi</ce:italic>1 restriction enzyme. The liver of the FAP patient (A002) and HepG2 cells was used as a control. (B) LC-MS/MS analysis of the D20 culture supernatant showed both TTR and ATTR at protein levels. Arrows indicate the wild-type TTR peaks. Asterisks indicate the ATTR Val30Met peaks.</ce:simple-para></ce:caption><ce:link locator="gr5" id="lk0025"/></ce:figure><ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="t0005" frame="topbot" colsep="0" rowsep="0"><ce:label>Table 1</ce:label><ce:caption id="ca0005"><ce:simple-para id="sp0015" view="all">Characterization of established clones.</ce:simple-para></ce:caption><tgroup cols="8"><colspec colname="col1"/><colspec colname="col2"/><colspec colname="col3"/><colspec colname="col4"/><colspec colname="col5"/><colspec colname="col6"/><colspec colname="col7"/><colspec colname="col8"/><thead><row valign="top" rowsep="1"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">Clone no.</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">Fibroblasts</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">Disease</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="left">P</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">Age/sex</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">SeV vector</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="left">Average induction efficiency (%)</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">Established SeV (-) clones</entry></row></thead><tbody><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">1</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">BJ</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">Normal</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="char" char=".">8</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">Neonatal/M</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">Kit</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="char" char=".">0.46</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">NT</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">2</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">Patient A002</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">FAP</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="char" char=".">11</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">51/F</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">Kit</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="char" char=".">0.054</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">30</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">3</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">Patient A003</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">FAP</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="char" char=".">9</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">33/F</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">Kit</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="char" char=".">0.41</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">36</entry></row><row valign="top"><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col1" align="left">4</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col2" align="left">Patient A004</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col3" align="left">FAP</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col4" align="char" char=".">12</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col5" align="left">44/F</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col6" align="left">Kit</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col7" align="char" char=".">0.12</entry><entry xmlns="http://www.elsevier.com/xml/common/dtd" colname="col8" align="left">33</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0020" view="all">Abbreviations: F, female; FAP, familial amyloidotic polyneuropathy; M, male; P, passage; SeV, Sendai virus.</ce:simple-para></ce:legend></ce:table></ce:floats><head><ce:article-footnote><ce:label>☆</ce:label><ce:note-para id="np0005" view="all">This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</ce:note-para></ce:article-footnote><ce:article-footnote><ce:label>☆☆</ce:label><ce:note-para id="np0010" view="all">Financial support: This work was supported by Grants-in-Aid for Scientific Research (A) 20253742 and (B) 20253742 from the <ce:grant-sponsor id="gts0005" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Ministry of Education, Science, Sports, and Culture of Japan</ce:grant-sponsor> (to YA), and by a grant from the <ce:grant-sponsor id="gts0010" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Institute of Biomedical Innovation</ce:grant-sponsor> (to NS), by a grant from <ce:grant-sponsor id="gts0015" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">CREST</ce:grant-sponsor> (to NS), and in part by a global COE grant (Cell Fate Regulation Research and Education Unit) from the <ce:grant-sponsor id="gts0020" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Ministry of Education, Culture, Sports, Science and Technology (MEXT) Japan</ce:grant-sponsor> (to SK). SK is a member of the Global COE Program (Cell Fate Regulation Research and Education Unit), MEXT, Japan. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This study was also supported in part by the <ce:grant-sponsor id="gts0025" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Japan Science and Technology Agency's Precursory Research for Embryonic Science and Technology and S-Innovation Programs</ce:grant-sponsor> (to NF), and by grants from the <ce:grant-sponsor id="gts0030" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Ministry of Health, Labor, and Welfare of Japan</ce:grant-sponsor> (to TE and NF).</ce:note-para></ce:article-footnote><ce:article-footnote><ce:label>★</ce:label><ce:note-para id="np0015" view="all">Conflict of interest: Nothing to report.</ce:note-para></ce:article-footnote><ce:title id="ti0005">Generation of familial amyloidotic polyneuropathy-specific induced pluripotent stem cells</ce:title><ce:author-group id="ag0005"><ce:author id="au0005"><ce:given-name>Kaori</ce:given-name><ce:surname>Isono</ce:surname><ce:cross-ref refid="af0005" id="cf0005"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="af0010" id="cf0010"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:cross-ref refid="fn0005" id="cf0015"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author id="au0010"><ce:given-name>Hirofumi</ce:given-name><ce:surname>Jono</ce:surname><ce:cross-ref refid="af0015" id="cf0020"><ce:sup loc="post">c</ce:sup></ce:cross-ref><ce:cross-ref refid="af0020" id="cf0025"><ce:sup loc="post">d</ce:sup></ce:cross-ref><ce:cross-ref refid="fn0005" id="cf0030"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author id="au0015"><ce:given-name>Yuki</ce:given-name><ce:surname>Ohya</ce:surname><ce:cross-ref refid="af0010" id="cf0035"><ce:sup loc="post">b</ce:sup></ce:cross-ref><ce:cross-ref refid="fn0005" id="cf0040"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author id="au0020"><ce:given-name>Nobuaki</ce:given-name><ce:surname>Shiraki</ce:surname><ce:cross-ref refid="af0025" id="cf0045"><ce:sup loc="post">e</ce:sup></ce:cross-ref><ce:cross-ref refid="fn0005" id="cf0050"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:author><ce:author id="au0025"><ce:given-name>Taiji</ce:given-name><ce:surname>Yamazoe</ce:surname><ce:cross-ref refid="af0025" id="cf0055"><ce:sup loc="post">e</ce:sup></ce:cross-ref></ce:author><ce:author id="au0030"><ce:given-name>Ayaka</ce:given-name><ce:surname>Sugasaki</ce:surname><ce:cross-ref refid="af0005" id="cf0060"><ce:sup loc="post">a</ce:sup></ce:cross-ref></ce:author><ce:author id="au0035"><ce:given-name>Takumi</ce:given-name><ce:surname>Era</ce:surname><ce:cross-ref refid="af0030" id="cf0065"><ce:sup loc="post">f</ce:sup></ce:cross-ref></ce:author><ce:author id="au0040"><ce:given-name>Noemi</ce:given-name><ce:surname>Fusaki</ce:surname><ce:cross-ref refid="af0035" id="cf0070"><ce:sup loc="post">g</ce:sup></ce:cross-ref><ce:cross-ref refid="af0040" id="cf0075"><ce:sup loc="post">h</ce:sup></ce:cross-ref><ce:cross-ref refid="af0045" id="cf0080"><ce:sup loc="post">i</ce:sup></ce:cross-ref></ce:author><ce:author id="au0045"><ce:given-name>Masayoshi</ce:given-name><ce:surname>Tasaki</ce:surname><ce:cross-ref refid="af0005" id="cf0085"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="af0015" id="cf0090"><ce:sup loc="post">c</ce:sup></ce:cross-ref></ce:author><ce:author id="au0050"><ce:given-name>Mitsuharu</ce:given-name><ce:surname>Ueda</ce:surname><ce:cross-ref refid="af0015" id="cf0095"><ce:sup loc="post">c</ce:sup></ce:cross-ref></ce:author><ce:author id="au0055"><ce:given-name>Satoru</ce:given-name><ce:surname>Shinriki</ce:surname><ce:cross-ref refid="af0015" id="cf0100"><ce:sup loc="post">c</ce:sup></ce:cross-ref></ce:author><ce:author id="au0060"><ce:given-name>Yukihiro</ce:given-name><ce:surname>Inomata</ce:surname><ce:cross-ref refid="af0010" id="cf0105"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author id="au0065"><ce:given-name>Shoen</ce:given-name><ce:surname>Kume</ce:surname><ce:cross-ref refid="af0025" id="cf0110"><ce:sup loc="post">e</ce:sup></ce:cross-ref><ce:cross-ref refid="cr0005" id="cf0115"><ce:sup loc="post">⁎</ce:sup></ce:cross-ref><ce:e-address id="em0005" type="email">skume@kumamoto-u.ac.jp</ce:e-address></ce:author><ce:author id="au0070"><ce:given-name>Yukio</ce:given-name><ce:surname>Ando</ce:surname><ce:cross-ref refid="af0005" id="cf0120"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="af0015" id="cf0125"><ce:sup loc="post">c</ce:sup></ce:cross-ref><ce:cross-ref refid="cr0010" id="cf0130"><ce:sup loc="post">⁎⁎</ce:sup></ce:cross-ref><ce:e-address id="em0010" type="email">andoy709@kumamoto-u.ac.jp</ce:e-address></ce:author><ce:affiliation id="af0005"><ce:label>a</ce:label><ce:textfn id="tn0005">Department of Neurology, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan</ce:textfn><sa:affiliation><sa:organization>Department of Neurology</sa:organization><sa:organization>Graduate School of Medical Science</sa:organization><sa:organization>Kumamoto University</sa:organization><sa:city>Kumamoto</sa:city><sa:country>Japan</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0010"><ce:label>b</ce:label><ce:textfn id="tn0010">Department of Transplantation and Pediatric Surgery, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan</ce:textfn><sa:affiliation><sa:organization>Department of Transplantation and Pediatric Surgery</sa:organization><sa:organization>Graduate School of Medical Science</sa:organization><sa:organization>Kumamoto University</sa:organization><sa:city>Kumamoto</sa:city><sa:country>Japan</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0015"><ce:label>c</ce:label><ce:textfn id="tn0015">Department of Diagnostic Medicine, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan</ce:textfn><sa:affiliation><sa:organization>Department of Diagnostic Medicine</sa:organization><sa:organization>Graduate School of Medical Science</sa:organization><sa:organization>Kumamoto University</sa:organization><sa:city>Kumamoto</sa:city><sa:country>Japan</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0020"><ce:label>d</ce:label><ce:textfn id="tn0020">Department of Pharmacy, Kumamoto University Hospital, Kumamoto University, Kumamoto, Japan</ce:textfn><sa:affiliation><sa:organization>Department of Pharmacy</sa:organization><sa:organization>Kumamoto University Hospital</sa:organization><sa:organization>Kumamoto University</sa:organization><sa:city>Kumamoto</sa:city><sa:country>Japan</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0025"><ce:label>e</ce:label><ce:textfn id="tn0025">Department of Stem Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan</ce:textfn><sa:affiliation><sa:organization>Department of Stem Cell Biology</sa:organization><sa:organization>Institute of Molecular Embryology and Genetics</sa:organization><sa:organization>Kumamoto University</sa:organization><sa:city>Kumamoto</sa:city><sa:country>Japan</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0030"><ce:label>f</ce:label><ce:textfn id="tn0030">Department of Cell Modulation, Institute of Molecular Embryology and Genetics, Kumamoto University, Kumamoto, Japan</ce:textfn><sa:affiliation><sa:organization>Department of Cell Modulation</sa:organization><sa:organization>Institute of Molecular Embryology and Genetics</sa:organization><sa:organization>Kumamoto University</sa:organization><sa:city>Kumamoto</sa:city><sa:country>Japan</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0035"><ce:label>g</ce:label><ce:textfn id="tn0035">DNAVEC Corporation, Ibaraki, Japan</ce:textfn><sa:affiliation><sa:organization>DNAVEC Corporation</sa:organization><sa:city>Ibaraki</sa:city><sa:country>Japan</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0040"><ce:label>h</ce:label><ce:textfn id="tn0040">Japan Science and Technology Agency (JST), PRESTO, Saitama, Japan</ce:textfn><sa:affiliation><sa:organization>Japan Science and Technology Agency (JST)</sa:organization><sa:organization>PRESTO</sa:organization><sa:city>Saitama</sa:city><sa:country>Japan</sa:country></sa:affiliation></ce:affiliation><ce:affiliation id="af0045"><ce:label>i</ce:label><ce:textfn id="tn0045">Ophthalmology, School of Medicine, Keio University, Japan</ce:textfn><sa:affiliation><sa:organization>Ophthalmology</sa:organization><sa:organization>School of Medicine</sa:organization><sa:organization>Keio University</sa:organization><sa:country>Japan</sa:country></sa:affiliation></ce:affiliation><ce:correspondence id="cr0005"><ce:label>⁎</ce:label><ce:text id="tx0005">Correspondence to: S. Kume, Department of Stem Cell Biology, Institute of Molecular Embryology and Genetics, Kumamoto University, Honjo 2-2-1, Chuo-ku, Kumamoto 860-0811, Japan.</ce:text></ce:correspondence><ce:correspondence id="cr0010"><ce:label>⁎⁎</ce:label><ce:text id="tx0010">Correspondence to: Y. Ando, Department of Neurology, Department of Diagnostic Medicine, Graduate School of Medical Science, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.</ce:text></ce:correspondence><ce:footnote id="fn0005"><ce:label>1</ce:label><ce:note-para id="np0020" view="all">These authors contributed equally to this work.</ce:note-para></ce:footnote></ce:author-group><ce:date-received day="13" month="3" year="2013"/><ce:date-revised day="13" month="12" year="2013"/><ce:date-accepted day="15" month="1" year="2014"/><ce:abstract id="ab0005" view="all" class="author"><ce:section-title id="st0005">Abstract</ce:section-title><ce:abstract-sec id="as0005" view="all"><ce:simple-para id="sp0005" view="all">Familial amyloidotic polyneuropathy (FAP) is a hereditary amyloidosis induced by amyloidogenic transthyretin (ATTR). Because most transthyretin (TTR) in serum is synthesized by the liver, liver transplantation (LT) is today the only treatment available to halt the progression of FAP, even though LT is associated with several problems. Despite the urgent need to develop alternatives to LT, the detailed pathogenesis of FAP is still unknown; also, no model fully represents the relevant processes in patients with FAP. The induction of induced pluripotent stem (iPS) cells has allowed development of pluripotent cells specific for patients and has led to useful models of human diseases. Because of the need for a tool to elucidate the molecular pathogenesis of FAP, in this study we sought to establish heterozygous ATTR mutant iPS cells, and were successful, by using a Sendai virus vector mixture containing four transcription factors (Oct3/4, Sox2, Klf4, and c-Myc) to reprogram dermal fibroblasts derived from FAP patients. Moreover, FAP-specific iPS cells had the potential to differentiate into hepatocyte-like cells and indeed expressed ATTR. FAP-specific iPS cells demonstrated the possibility of serving as a pathological tool that will contribute to understanding the pathogenesis of FAP and development of FAP treatments.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:abstract class="author-highlights" id="ab0010" view="all"><ce:section-title id="st0010">Highlights</ce:section-title><ce:abstract-sec id="as0010" view="all"><ce:simple-para id="sp0010" view="all"><ce:list id="l0005"><ce:list-item id="u0005"><ce:label>•</ce:label><ce:para id="p0230" view="all">We established, for the first time, FAP-specific iPS cells by using a Sendai virus.</ce:para></ce:list-item><ce:list-item id="u0010"><ce:label>•</ce:label><ce:para id="p0235" view="all">FAP-specific iPS cells have potential to differentiate into hepatocyte-like cells.</ce:para></ce:list-item><ce:list-item id="u0015"><ce:label>•</ce:label><ce:para id="p0240" view="all">Hepatocyte-like cells from FAP-specific iPS cells indeed expressed ATTR Val30Met.</ce:para></ce:list-item><ce:list-item id="u0020"><ce:label>•</ce:label><ce:para id="p0245" view="all">FAP-specific iPS cells demonstrate the possibility to serve as a pathological tool.</ce:para></ce:list-item></ce:list></ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords id="ks0005" class="abr" view="all"><ce:section-title id="st0015">Abbreviations</ce:section-title><ce:keyword id="kw0100"><ce:text id="tx0015">ALP</ce:text><ce:keyword id="kw0105"><ce:text id="tx0020">alkaline phosphatase</ce:text></ce:keyword></ce:keyword><ce:keyword id="kw0110"><ce:text id="tx0025">ATTR</ce:text><ce:keyword id="kw0115"><ce:text id="tx0030">amyloidogenic transthyretin</ce:text></ce:keyword></ce:keyword><ce:keyword id="kw0120"><ce:text id="tx0035">FAP</ce:text><ce:keyword id="kw0125"><ce:text id="tx0040">familial amyloidotic polyneuropathy</ce:text></ce:keyword></ce:keyword><ce:keyword id="kw0130"><ce:text id="tx0045">LT</ce:text><ce:keyword id="kw0135"><ce:text id="tx0050">liver transplantation</ce:text></ce:keyword></ce:keyword><ce:keyword id="kw0140"><ce:text id="tx0055">SELDI-TOF MS</ce:text><ce:keyword id="kw0145"><ce:text id="tx0060">surface-enhanced laser desorption/ionization time-of-flight mass spectrometry</ce:text></ce:keyword></ce:keyword><ce:keyword id="kw0150"><ce:text id="tx0065">SeV</ce:text><ce:keyword id="kw0155"><ce:text id="tx0070">Sendai virus</ce:text></ce:keyword></ce:keyword><ce:keyword id="kw0160"><ce:text id="tx0075">TTR</ce:text><ce:keyword id="kw0165"><ce:text id="tx0080">transthyretin</ce:text></ce:keyword></ce:keyword></ce:keywords></head><body view="all"><ce:sections><ce:section id="s0005" view="all"><ce:section-title id="st0025">Introduction</ce:section-title><ce:para id="p0005" view="all">Transthyretin (TTR) is a β-sheet-rich protein that is mainly synthesized by the liver (<ce:cross-ref refid="bb0060" id="cf0135">Buxbaum and Reixach, 2009</ce:cross-ref>). TTR normally serves as a plasma transport protein for thyroid hormone and retinol-binding protein with vitamin A (<ce:cross-ref refid="bb0115" id="cf0140">Kanai et al., 1968</ce:cross-ref>). Mutant forms of TTR, however, cause familial amyloidotic polyneuropathy (FAP), which is the most common type of autosomal-dominant hereditary systemic amyloidosis (<ce:cross-refs refid="bb0165 bb0035" id="cf0145">Saraiva et al., 1983; Ando et al., 2005</ce:cross-refs>). As of today, more than 100 different points of mutation and a deletion in the TTR gene have been reported (<ce:cross-refs refid="bb0235 bb0010 bb0050" id="cf0150">Westermark et al., 2002; Ando and Ueda, 2012; Benson and Kincaid, 2007</ce:cross-refs>), with the Val30Met mutation being the most common. Systemic amyloid depositions in FAP cause various symptoms, including cardiac and renal dysfunctions, gastrointestinal disorders, glandular and autonomic dysfunctions, and peripheral neuropathy (<ce:cross-refs refid="bb0005 bb0015 bb0030 bb0040" id="cf0155">Ando and Suhr, 1998; Ando et al., 1993, 1997; Araki, 1984</ce:cross-refs>). Because the liver synthesizes most of the TTR in the serum, liver transplantation (LT) is the only treatment available to halt the progression of FAP (<ce:cross-refs refid="bb0020 bb0210" id="cf0160">Ando et al., 1995a; Suhr et al., 1995</ce:cross-refs>). Although LT is widely accepted as the only lifesaving treatment option for FAP patients (<ce:cross-ref refid="bb0025" id="cf0165">Ando et al., 1995b</ce:cross-ref>), LT involves several problems, such as a shortage of liver donors, the effects of immunosuppressants, and the progression of ocular disorders caused by a continuing production of amyloidogenic TTR (ATTR) by the retina (<ce:cross-refs refid="bb0145 bb0125" id="cf0170">Ong et al., 1994; Kawaji et al., 2005</ce:cross-refs>).</ce:para><ce:para id="p0010" view="all">Despite an urgent need to develop alternatives to LT, details about the mechanism of amyloid formation in FAP are still unknown. Although attempts were made to establish experimental models of FAP, a suitable tool is not yet available (<ce:cross-refs refid="bb0065 bb0150 bb0055" id="cf0175">Buxbaum et al., 2003; Pokrzywa et al., 2007; Berg et al., 2009</ce:cross-refs>). Because FAP is an autosomal-dominant inherited disease, TTR secreted into plasma is the heterotetrameric mixture of wild-type TTR and variant TTR. However, all TTRs used in experiments have been homotetramers, and an artificial Val30Met-overexpressed cell system does not fully represent the relevant processes in patients with FAP (<ce:cross-refs refid="bb0195 bb0070 bb0170" id="cf0180">Sousa et al., 2000; Cardoso et al., 2008; Sato et al., 2007</ce:cross-refs>). Therefore, an urgent need exists to establish an experimental model such as heterozygous ATTR mutant cells derived from FAP patients.</ce:para><ce:para id="p0015" view="all">Induced pluripotent stem (iPS) cells have an unlimited replicative ability and the potential to differentiate into most cell types in organisms (<ce:cross-refs refid="bb0220 bb0225 bb0255" id="cf0185">Takahashi and Yamanaka, 2006; Takahashi et al., 2007; Yu et al., 2007</ce:cross-refs>). The creation of iPS cells has permitted the development of patient-specific pluripotent cells and has led to useful models of human diseases (<ce:cross-ref refid="bb0160" id="cf0190">Saha and Jaenisch, 2009</ce:cross-ref>). Recent studies reported success in generating patient-specific iPS cells for various diseases including neurologic (<ce:cross-refs refid="bb0075 bb0080 bb0190" id="cf0195">Dimos et al., 2008; Ebert et al., 2009; Soldner et al., 2009</ce:cross-refs>), hematologic (<ce:cross-ref refid="bb0155" id="cf0200">Raya et al., 2009</ce:cross-ref>), and metabolic disorders (<ce:cross-ref refid="bb0135" id="cf0205">Maehr et al., 2009</ce:cross-ref>). A report on spinal muscular atrophy-specific iPS cells suggested applications to disease modeling and drug screening by showing the disease-specific changes in cell survival and function (<ce:cross-ref refid="bb0080" id="cf0210">Ebert et al., 2009</ce:cross-ref>). A report on Fanconi anemia-specific iPS cells also indicated a potential value for cell therapy by correcting the genetic defect before iPS cell derivation (<ce:cross-ref refid="bb0155" id="cf0215">Raya et al., 2009</ce:cross-ref>). Thus, although disease-specific iPS cells may help therapeutic research, iPS cells from patients with FAP have not yet been generated.</ce:para><ce:para id="p0020" view="all">In this study, we first report the generation of iPS cells from patients with FAP ATTR Val30Met, which we achieved by reprogramming their fibroblasts with a mixture of Sendai virus (SeV) vector, which does not integrate into the host genome (<ce:cross-ref refid="bb0130" id="cf0220">Li et al., 2000</ce:cross-ref>) and has a low risk of tumorigenicity, encoding four transcription factors: octamer 3/4 (Oct3/4), sex-determining region Y box 2 (Sox2), Kruppel-like factor 4 (Klf4), and c-Myc (<ce:cross-refs refid="bb0085 bb0045" id="cf0225">Fusaki et al., 2009; Ban et al., 2011</ce:cross-refs>). FAP-specific iPS cells indeed differentiated into hepatocyte-like cells (<ce:cross-refs refid="bb0180 bb0185" id="cf0230">Shiraki et al., 2008; Shiraki et al., 2011</ce:cross-refs>) and expressed Val30Met ATTR. FAP-specific iPS cells may thus provide valuable experimental tools to elucidate the molecular pathogenesis of FAP with a potential value for cell therapy applications.</ce:para></ce:section><ce:section id="s0010" view="all"><ce:section-title id="st0030">Materials and methods</ce:section-title><ce:section id="s0030" view="all"><ce:section-title id="st0060">Reagents</ce:section-title><ce:para id="p0030" view="all">Reagents were purchased and used at the designated concentrations as follows: recombinant human Activin A (HumanZyme, Chicago, IL), 100<ce:hsp sp="0.25"/>ng/ml; recombinant human basic fibroblast growth factor (ReproCELL, Yokohama, Japan); recombinant human Bone morphogenetic protein 4 (R&amp;D systems, Minneapolis, MN), 10<ce:hsp sp="0.25"/>ng/ml; recombinant human Fibroblast growth factor 10 (PeproTech, London, UK), 10<ce:hsp sp="0.25"/>ng/ml; recombinant human hepatocyte growth factor (PeproTech), 10<ce:hsp sp="0.25"/>ng/ml; dexamethasone (Dex; Sigma, St. Louis, MO), 1<ce:hsp sp="0.25"/>μM; Y-27632 (Rho-associated kinase inhibitor; Wako Chemical, Osaka, Japan), 10<ce:hsp sp="0.25"/>μM; Dulbecco's Modified Eagle Medium (Gibco, Funakoshi, Tokyo, Japan); RPMI-1640 (Invitrogen, Glasgow, UK); B27 supplement (Invitrogen), nonessential amino acids (Gibco); <ce:small-caps>l</ce:small-caps>-glutamine (Gibco); knockout serum replacement (Gibco); polyclonal rabbit anti-human TTR antibody (Dako, Glostrup, Denmark); Mouse anti-Oct3/4 antibody (Santa Cruz Biotechnology, Texas, USA), Rabbit anti-Alphafeto protein antibody (Dako), Goat anti-human Albumin antibody (Bethyl, Texas, USA), Goat anti-Sox17 antibody (R&amp;D systems); and Rabbit anti-HNF-4α antibody (Santa Cruz Biotechnology).</ce:para></ce:section><ce:section id="s0035" view="all"><ce:section-title id="st0065">Patients</ce:section-title><ce:para id="p0040" view="all">Skin biopsy samples were obtained from three Japanese female patients with FAP ATTR Val30Met in Kumamoto University Hospital. All FAP patients in this study had a definitive diagnosis of FAP on the basis of genetic investigations and clinical manifestations of FAP (<ce:cross-ref refid="t0005" id="cf0235">Table 1</ce:cross-ref><ce:float-anchor refid="t0005"/>). The research followed the guidelines of the Kumamoto University Ethical Committee.</ce:para></ce:section><ce:section id="s0040" view="all"><ce:section-title id="st0070">Generation of iPS cells</ce:section-title><ce:para id="p0050" view="all">Skin fibroblasts from patients with FAP ATTR Val30Met were maintained in Dulbecco's Modified Eagle Medium (Gibco) supplemented with 10% fetal bovine serum. Induction of human iPS cells was performed as described previously (<ce:cross-refs refid="bb0085 bb0045" id="cf0240">Fusaki et al., 2009; Ban et al., 2011</ce:cross-refs>). In brief, 1<ce:hsp sp="0.25"/>×<ce:hsp sp="0.25"/>10<ce:sup loc="post">6</ce:sup> human fibroblasts BJ from neonatal foreskin (American Type Culture Collection, Manassas, VA) or FAP patients' fibroblasts were infected with conventional SeV vectors carrying Oct3/4, Sox2, Klf 4, and a temperature-sensitive vector, which has c-Myc at the HNL position at a multiplicity of infection of 3. One week after infection, cells were collected and replated on mitomycin C-treated mouse embryonic fibroblast feeder cells. The next day, medium was changed to a primate embryonic stem cell medium supplemented with 10<ce:hsp sp="0.25"/>ng/ml basic fibroblast growth factor. Embryonic stem cell-like colonies were picked up 28<ce:hsp sp="0.25"/>days after infection. At passage 3, many colonies were negative for the SeV vector; if the vector was present, SeV-negative clones were obtained by incubating cells at nonpermissive temperature (38<ce:hsp sp="0.25"/>°C for 3<ce:hsp sp="0.25"/>days). The reprogramming efficiency was calculated as the number of alkaline phosphatase (ALP)-positive embryonic stem cell-like colonies formed per number of infected cells seeded.</ce:para></ce:section><ce:section id="s0045" view="all"><ce:section-title id="st0075">Differentiation into hepatocyte-like cells</ce:section-title><ce:para id="p0060" view="all">FAP-specific iPS cells were differentiated into hepatocyte-like cells using feeder free method modified from reported protocols (<ce:cross-refs refid="bb0180 bb0185" id="cf0245">Shiraki et al., 2008, 2011</ce:cross-refs>), with the following modifications: FAP-specific iPS cells were pretreated overnight with 10<ce:hsp sp="0.25"/>μM Y-27632 (Wako Chemical) and were then dissociated by using 0.25% trypsin-EDTA and were plated at 100,000 cells per well in 96-well plates that had been previously coated with fibronectin. The cells were cultured for 5<ce:hsp sp="0.25"/>days in DMEM supplemented with 100<ce:hsp sp="0.25"/>ng/ml Activin A (HumanZyme), 2% B27 supplement (Invitrogen), nonessential amino acids (Gibco), <ce:small-caps>l</ce:small-caps>-glutamine (Gibco), penicillin and streptomycin, and β-mercaptoethanol. For differentiation from D5 to D7, RPMI-1640 (Invitrogen) supplemented with 10<ce:hsp sp="0.25"/>ng/ml BMP4, 10<ce:hsp sp="0.25"/>ng/ml Fgf10 and 2% B27 supplement, nonessential amino acids (Gibco), <ce:small-caps>l</ce:small-caps>-glutamine (Gibco), penicillin and streptomycin, and β-mercaptoethanol. The medium was then changed to hepatic differentiation medium-DMEM supplemented with 10% knockout serum replacement (Gibco), 10<ce:hsp sp="0.25"/>ng/ml hepatocyte growth factor (PeproTech), 1<ce:hsp sp="0.25"/>μM Dex (Sigma), nonessential amino acids, <ce:small-caps>l</ce:small-caps>-glutamine, penicillin and streptomycin, and β-mercaptoethanol-for up to 20<ce:hsp sp="0.25"/>days. Medium was replaced every day (Day 0-5) or every 2<ce:hsp sp="0.25"/>days (Day 5-20) with fresh differentiation medium supplemented with growth factor. Human iPS cell lines (201B7), the first iPS cells established from human dermal fibroblasts by Dr. Shinya Yamanaka, and HepG2 cells, a human hepatocellular carcinoma cell line, were used as control (<ce:cross-ref refid="bb0225" id="cf0250">Takahashi et al., 2007</ce:cross-ref>). For albumin and TTR secretion assay, definitive endoderm cells (Day 5) were dissociated with 0.25% trypsin-EDTA (Invitrogen) and then plated at 200,000 cells/well on a synthemax (corning) pre-coated 96-well plate, and culture up to Day 20 using the abovementioned protocol.</ce:para></ce:section><ce:section id="s0050" view="all"><ce:section-title id="st0080">ALP staining</ce:section-title><ce:para id="p0070" view="all">ALP staining was performed with ALP substrate (1-Step NBT/BCIP; Pierce, IL, USA) after fixation with 10% neutral buffered formalin solution (Wako Chemical), as previously described (<ce:cross-refs refid="bb0085 bb0045" id="cf0255">Fusaki et al., 2009; Ban et al., 2011</ce:cross-refs>).</ce:para></ce:section><ce:section id="s0055" view="all"><ce:section-title id="st0085">Reverse-transcription polymerase chain reaction (RT-PCR) analysis</ce:section-title><ce:para id="p0080" view="all">RNA extraction, cDNA synthesis, and RT-PCR were performed as described previously (<ce:cross-refs refid="bb0085 bb0180" id="cf0260">Fusaki et al., 2009; Shiraki et al., 2008</ce:cross-refs>). The following primers were used: NANOG homeobox (NANOG): forward 5′-TACCTCAGCCTCCAGCAGAT-3′, reverse 5′-TGCGTCACACCATTGCTATT-3′; telomerase reverse transcriptase (TERT): forward 5′-TGCCCGGACCTCCATCAGAGCCAG-3′, reverse 5′-TCAGTCCAGGATGGTCTTGAAGTCTG-3′; SeV: forward 5′-TGGCTAAGAACATCGGAAGG-3′, reverse 5′-GTTTTGCAACCAAGCACTCA-3′; and β-actin: forward 5′-CAACCGCGAGAAGATGAC-3′, reverse 5′-AGGAAGGCTGGAAGAGTG-3′.</ce:para></ce:section><ce:section id="s0060" view="all"><ce:section-title id="st0090">Real-time PCR analysis</ce:section-title><ce:para id="p0090" view="all">The real-time PCR conditions were as follows: denaturation at 95<ce:hsp sp="0.25"/>°C for 15<ce:hsp sp="0.25"/>s and annealing and extension at 60<ce:hsp sp="0.25"/>°C for 60<ce:hsp sp="0.25"/>s, for up to 40<ce:hsp sp="0.25"/>cycles. Target messenger RNA (mRNA) levels were expressed as arbitrary units and were determined by using the standard curve method. The following primers were used: Oct3/4: forward 5′-AGGTGTGGGGGATTCCCCCAT-3′, reverse 5′-GCGATGTGGCTGATCTGCTGC-3′; Sox17: forward 5′-ACTGCAACTATCCTGACGTG-3′, reverse 5′-AGGAAATGGAGGAAGCTGTT-3′; alpha-fetoprotein (AFP): forward 5′-TGCCAACTCAGTGAGGACAA-3′, reverse 5′-TCCAACAGGCCTGAGAAATC-3′; albumin (ALB): forward 5′-GATGTCTTCCTGGGCATGTT-3′, reverse 5′-ACATTTGCTGCCCACTTTTC-3′; TTR: forward 5′-CATTCTTGGCAGGATGGCTTC-3′, reverse 5′-CT CCCAGGTGTC ATCAGCAG-3′; and GAPDH: forward 5′-CGAGATCCCTCCAAAATCAA-3′, reverse 5′-CATGAGTCCTTCCACGATACCAA-3′.</ce:para></ce:section><ce:section id="s0065" view="all"><ce:section-title id="st0095">Immunocytochemistry</ce:section-title><ce:para id="p0100" view="all">For whole-mount immunocytochemical analysis, iPS cell cultures were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 30<ce:hsp sp="0.25"/>min, followed by permeabilization with 0.1% Triton-X (Nakalai Tesque) in PBS for 10<ce:hsp sp="0.25"/>min at room temperature, rinsed several times with PBS then incubated with diluted antibody in 20% Blocking One (Nakalai Tesque) in PBST (0.1% Tween-20 in PBS) in a humidified chamber overnight at 4<ce:hsp sp="0.25"/>°C. Cells were washed in PBST, and incubated with secondary antibody in 20% Blocking One for 2<ce:hsp sp="0.25"/>h at room temperature in the dark. After washing off the secondary antibody in PBST, cells were counterstained with 6-diamidino-2-phenylindole (DAPI) (Roche Diagnostics, Indianapolis, IN). The following antibodies were used as first antibodies: rabbit anti-AFP (Dako), Goat anti-human Albumin antibody (Bethyl), anti-Oct3/4 antibody (Santa Cruz Biotechnology), goat anti-Sox17 antibody (R&amp;D systems), rabbit anti-HNF-4α antibody (Santa Cruz Biotechnology), and anti-HN monoclonal antibody IL4.1 (<ce:cross-ref refid="bb0085" id="cf0265">Fusaki et al., 2009</ce:cross-ref>). Secondary antibodies used were Alexa 568-conjugated and Alexa 488-conjugated antibodies (Invitrogen). To assess the efficiency of differentiation, Sox17-, AFP-, and ALB-positive cells versus total cells (DAPI-positive cells) were quantified using ImageXpress Micro cellular imaging system (Molecular Devices Sunnyvale, CA).</ce:para></ce:section><ce:section id="s0070" view="all"><ce:section-title id="st0100">PAS analysis</ce:section-title><ce:para id="p0110" view="all">The cultured cells were fixed in 3.3% formalin for 10<ce:hsp sp="0.25"/>min, and intracellular glycogen was stained using a PAS staining solution (Muto Pure Chemicals, Tokyo, Japan), according to the manufacturer's instructions.</ce:para></ce:section><ce:section id="s0075" view="all"><ce:section-title id="st0105">Albumin secretion assay</ce:section-title><ce:para id="p0120" view="all">The differentiation medium was changed to fresh medium 48<ce:hsp sp="0.25"/>h before the assay. Albumin secretion was measured by the central clinical laboratory at Kumamoto University, Kumamoto, Japan.</ce:para></ce:section><ce:section id="s0080" view="all"><ce:section-title id="st0110">PCR-restriction fragment length polymorphism analysis (PCR-RFLP)</ce:section-title><ce:para id="p0130" view="all">Extraction of RNA from HepG2 cells and the frozen samples of livers from FAP patients A002 and cDNA synthesis were performed as previously described (<ce:cross-ref refid="bb0085" id="cf0270">Fusaki et al., 2009</ce:cross-ref>). RNA was extracted from FAP-specific iPS cells with the RNeasy Micro Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol, and cDNA synthesis was performed as described elsewhere (<ce:cross-ref refid="bb0205" id="cf0275">Sueyoshi et al., 2012</ce:cross-ref>). PCR primers, which were the same as those used in the real-time PCR reaction, were designed to amplify the Val30Met mutation in exon 2 of the TTR gene. The PCR conditions were 5<ce:hsp sp="0.25"/>min at 98<ce:hsp sp="0.25"/>°C; 35<ce:hsp sp="0.25"/>cycles at 94<ce:hsp sp="0.25"/>°C for 30<ce:hsp sp="0.25"/>s, 55<ce:hsp sp="0.25"/>°C for 30<ce:hsp sp="0.25"/>s, and 72<ce:hsp sp="0.25"/>°C for 1<ce:hsp sp="0.25"/>min; followed by 7<ce:hsp sp="0.25"/>min at 72<ce:hsp sp="0.25"/>°C. The PCR product of 199<ce:hsp sp="0.25"/>bp was digested at 37<ce:hsp sp="0.25"/>°C for 2<ce:hsp sp="0.25"/>h with 5<ce:hsp sp="0.25"/>U <ce:italic>Nsi</ce:italic>1 restriction enzyme (New England Biolabs, Ipswich, MA, USA), which recognized the mutation site. PCR products were evaluated via a microchip electrophoresis system (Cosmo-I SV1210; Hitachi Electronics Engineering, Tokyo, Japan). Measurements were obtained according to the manufacturer's manual.</ce:para></ce:section><ce:section id="s0085" view="all"><ce:section-title id="st0115">Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS)</ce:section-title><ce:para id="p0140" view="all">Serum specimens and culture supernatants were evaluated with the PCS 4000 SELDI-TOF MS instrument (Bio-Rad Laboratories, Hercules, CA, USA) by using the following protocol (<ce:cross-ref refid="bb0230" id="cf0280">Ueda et al., 2009</ce:cross-ref>), unless otherwise specified: ion focus mass, 13,800<ce:hsp sp="0.25"/><ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>; laser energy, 2000<ce:hsp sp="0.25"/>nJ; matrix attenuation, 500<ce:hsp sp="0.25"/><ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>; sample rate, 800; shots/pixel, 5; partition, 1 of 4; and acquired mass range from 0 to 100,000<ce:hsp sp="0.25"/><ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>. Baseline smoothing: smoothing before fitting baseline, window 25 points. Baseline width: automatic. These baseline settings were the default settings. External calibration of the instrument was performed by using the All-in-One protein molecular mass standard (Bio-Rad Laboratories). Conditions: Q10 ProteinChip in 50<ce:hsp sp="0.25"/>mmol/l phosphate buffer, pH<ce:hsp sp="0.25"/>7.0.</ce:para></ce:section><ce:section id="s0090" view="all"><ce:section-title id="st0120">Liquid chromatography-tandem mass spectrometry (LC-MS/MS)</ce:section-title><ce:para id="p0150" view="all">The Amicon Ultra centrifugal filter 10<ce:hsp sp="0.25"/>K (Millipore, Billerica, MA, USA) was used to make 7-10-fold concentrated culture supernatants. The concentration was incubated overnight at 4<ce:hsp sp="0.25"/>°C with 5<ce:hsp sp="0.25"/>μg of polyclonal rabbit anti-human TTR antibody (Dako). PureProteome Protein G Magnetic Beads (Millipore) were added to the reaction to capture the immune complexes and were agitated for 2<ce:hsp sp="0.25"/>h at 4<ce:hsp sp="0.25"/>°C. After the immune complexes were washed three times with PBST, 25<ce:hsp sp="0.25"/>μl of sample buffer (Bio-Rad Laboratories) was added and incubation proceeded for 5<ce:hsp sp="0.25"/>min at 95<ce:hsp sp="0.25"/>°C. Sample buffers (25<ce:hsp sp="0.25"/>μl), which eluted TTR protein from the beads, were fractionated via sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Silver staining of gels was performed with ProteoSilver<ce:sup loc="post">TM</ce:sup> Plus Silver Stain Kit (Sigma-Aldrich) according to the manufacturer's protocol. The bands of TTR were excised from the gel, destained according to the manufacturer's protocol, digested with sequence-grade modified trypsin (Promega, Madison, WI). The peptide mixtures were dried and redissolved with 40<ce:hsp sp="0.25"/>μl of MS-grade water containing 0.1% trifluoroacetic acid and 2% acetonitrile, and were used for nano-flow reversed-phase LC-MS/MS (LTQ Velos Pro; Thermo Fisher Scientific, San Jose, CA). A capillary reversed-phase LC-MS/MS system composed of an Advance Splitless Nano-Capillary LC dual solvent delivery system (Bruker-Michrom, Auburn, CA), an HTS-xt PAL autosampler (CTC Analytics, Zwingen, Switzerland), and LTQ Velos Pro equipped with an XYZ nanoelectrospray ionization source (AMR, Tokyo, Japan) was used. The samples were injected into a peptide L-trap column (Chemical Evaluation Research Institute, Tokyo, Japan). The peptides were separated by using a capillary reversed-phase C18 column (Chemical Evaluation Research Institute) with gradient elution and an ion spray into the mass spectrometer at a spray voltage of 2.3<ce:hsp sp="0.25"/>kV. The peptide and fragment mass tolerances were 2.0<ce:hsp sp="0.25"/>Da and 0.8<ce:hsp sp="0.25"/>Da, respectively. To calculate the ratios of wild-type TTR and ATTR to total TTR in culture supernatants, we measured the areas of the peptide mass peaks derived from wild-type TTR and ATTR, respectively. Peptides (22-34 peptides; GSPAINVAVHVFR) derived from wild-type TTR had a molecular mass of 684<ce:hsp sp="0.25"/><ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>. Peptides (22-34 peptides; GSPAINVAMHVFR) derived from ATTR had a molecular mass of 700<ce:hsp sp="0.25"/><ce:italic>m</ce:italic>/<ce:italic>z</ce:italic>.</ce:para></ce:section><ce:section id="s0095" view="all"><ce:section-title id="st0125">Western blotting</ce:section-title><ce:para id="p0160" view="all">As described in the LC-MS/MS section, the immune complexes, made from 20-fold concentrated culture supernatants, were washed three times with PBS, 20<ce:hsp sp="0.25"/>μl of sample buffer (Bio-Rad Laboratories) was added and incubation proceeded for 5<ce:hsp sp="0.25"/>min at 95<ce:hsp sp="0.25"/>°C. Sample buffers (10<ce:hsp sp="0.25"/>μl), which eluted TTR protein from the beads, were fractionated via sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (GE Healthcare, Buckinghamshire, UK). Membranes were blocked with 5% nonfat dried milk and PBST and were then incubated overnight at 4<ce:hsp sp="0.25"/>°C with antibodies against TTR in 5% bovine serum albumin (Sigma) and PBST. After the membranes were washed, they were incubated in biotinylated secondary antibodies for 1<ce:hsp sp="0.25"/>h and then in horseradish peroxidase-conjugated streptavidin for 1<ce:hsp sp="0.25"/>h. After this process, specific protein bands were detected with an enhanced chemiluminescence system (Amersham Pharmacia Biotech, Buckinghamshire, UK).</ce:para></ce:section><ce:section id="s0100" view="all"><ce:section-title id="st0130">Enzyme-Linked ImmunoSorbent Assay (ELISA)</ce:section-title><ce:para id="p0170" view="all">The concentration of TTR protein in the media of differentiated FAP-specific iPS cells was measured by ELISA assay. The differentiation medium was changed to fresh medium 48<ce:hsp sp="0.25"/>h before the assay. The wells of Nunc-Immuno<ce:sup loc="post">TM</ce:sup> plate II (Thermo Fisher Scientific) were coated with 7000-fold dilution of TTR sheep anti-human polyclonal antibody (LifeSpan BioSciences, Seattle, USA) in carbonate/bicarbonate buffer and incubated overnight at 4<ce:hsp sp="0.25"/>°C. The coating buffer was removed and the wells were washed three times with 200<ce:hsp sp="0.25"/>μl PBST. 250<ce:hsp sp="0.25"/>μl blocking buffer and 0.5% gelatin in the coating buffer were added per well and incubated for 1<ce:hsp sp="0.25"/>h at room temperature. The blocking buffer was removed and the wells were washed as described above. 100<ce:hsp sp="0.25"/>μl of appropriately diluted samples and serum as the standard were added to each well and incubated for 1<ce:hsp sp="0.25"/>h at room temperature. The samples and standard were removed and the wells were washed as described above. 100<ce:hsp sp="0.25"/>μl of 10,000-fold diluted polyclonal rabbit anti-human TTR antibody (Dako) in 0.5% gelatin in the PBST was added to each well and incubated for 1<ce:hsp sp="0.25"/>h at room temperature. The detection antibody was removed and wells were washed as described above. 100<ce:hsp sp="0.25"/>μl of 5000-fold diluted polyclonal goat anti-rabbit immunoglobulins/HRP (Dako) in 0.5% gelatin in the PBST was added to each well and incubated for 1<ce:hsp sp="0.25"/>h at room temperature. The secondary antibody was removed and the wells washed as described above. 100<ce:hsp sp="0.25"/>μl of TMB (KPL, Gaithersburg, USA) solution was added to each well and 1 and half min later, equal volume of stop solution (1<ce:hsp sp="0.25"/>M HCL) was added and read the optical density at 450<ce:hsp sp="0.25"/>nm.</ce:para></ce:section></ce:section><ce:section id="s0015" view="all"><ce:section-title id="st0035">Results</ce:section-title><ce:section id="s0105" view="all"><ce:section-title id="st0135">Generation of iPS cells from patients with FAP</ce:section-title><ce:para id="p0180" view="all">Dermal fibroblasts obtained from heterozygotic FAP Val30Met patients (<ce:cross-ref refid="t0005" id="cf0285">Table 1</ce:cross-ref>) were cultured and infected with SeV vectors encoding the reprogramming factors Oct3/4, Sox2, Klf4, and c-Myc. Forms of TTR in the serum of one FAP patient (A002) were analyzed by using SELDI-TOF MS, which detected peaks of approximately 13,761<ce:hsp sp="0.25"/>Da for wild-type TTR and 13,792<ce:hsp sp="0.25"/>Da for ATTR Val30Met (<ce:cross-ref refid="f0005" id="cf0290">Fig. 1</ce:cross-ref><ce:float-anchor refid="f0005"/>). The reprogrammed cells were positive for ALP activity (<ce:cross-ref refid="f0010" id="cf0295">Fig. 2</ce:cross-ref>A<ce:float-anchor refid="f0010"/>). RT-PCR confirmed the expression of pluripotency markers such as NANOG and TERT in FAP-specific iPS cells. SeV vectors were diluted during cell growth and removed after the temperature shift treatment (at 38<ce:hsp sp="0.25"/>°C for 3<ce:hsp sp="0.25"/>days) (<ce:cross-ref refid="f0010" id="cf0300">Fig. 2</ce:cross-ref>B). Immunostaining with the antibody against SeV protein demonstrated the clones free of viral proteins (<ce:cross-ref refid="f0010" id="cf0305">Fig. 2</ce:cross-ref>C). The reprogrammed cells exhibited the ES-like morphology and the expression of pluripotency marker Oct3/4 was confirmed by immunostaining (<ce:cross-ref refid="f0010" id="cf0310">Fig. 2</ce:cross-ref>D). The induction efficiency of FAP-specific iPS cells ranged from 0.054% to 0.41% for each individual (<ce:cross-ref refid="t0005" id="cf0315">Table 1</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0110" view="all"><ce:section-title id="st0140">Differentiation of FAP-specific iPS cells into hepatocyte-like cells</ce:section-title><ce:para id="p0190" view="all">For cell differentiation, FAP-specific iPS cells were cultured with serial changes of media as shown in <ce:cross-ref refid="f0015" id="cf0320">Fig. 3</ce:cross-ref>A<ce:float-anchor refid="f0015"/>. To test whether FAP-specific iPS cells can differentiate into hepatocyte-like cells, we analyzed several markers via real-time PCR analysis on Day 5 (D5), D13 and D20 differentiated FAP-specific iPS cells (<ce:cross-ref refid="f0015" id="cf0325">Fig. 3</ce:cross-ref>B). A decrease in expression of the pluripotency marker Oct3/4 was accompanied by differentiation of FAP-specific iPS cells. Expression of the endoderm marker Sox17 was observed on D5 differentiation and decreased gradually after the medium was changed to hepatic differentiation medium on D7 (<ce:cross-ref refid="f0015" id="cf0330">Fig. 3</ce:cross-ref>B). The hepatic progenitor marker AFP and the mature hepatocyte marker ALB were obviously expressed on D13 and D20. In addition, immunocytochemical analyses showed Sox17 expression on D5, both HNF-4α and AFP expression on D13, and ALB cytoplasmic staining on D20 (<ce:cross-ref refid="f0015" id="cf0335">Fig. 3</ce:cross-ref>C). Quantitative imaging analysis revealed that approximately 78<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>0.6% of cells were Sox17-positive on D5 and approximately 88<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>1.1% of cells were AFP-positive on D13 and approximately 29<ce:hsp sp="0.25"/>±<ce:hsp sp="0.25"/>0.9% of cells were ALB-positive on D20 (<ce:cross-ref refid="f0015" id="cf0340">Fig. 3</ce:cross-ref>D). The ALB secretion in the media of differentiated FAP-specific iPS cells on D20 was approximately 20<ce:hsp sp="0.25"/>μg/ml (<ce:cross-ref refid="f0015" id="cf0345">Fig. 3</ce:cross-ref>E). Moreover, these D20 differentiated FAP-specific iPS cells were also periodic acid-Schiff (PAS)-positive, indicating cytoplasmic glycogen storage (<ce:cross-ref refid="f0015" id="cf0350">Fig. 3</ce:cross-ref>F). These results clearly indicated that FAP-specific iPS cells had the potential to differentiate into hepatocyte-like cells.</ce:para></ce:section><ce:section id="s0115" view="all"><ce:section-title id="st0145">Production of wild-type TTR and ATTR Val30Met by differentiated hepatocyte-like cells</ce:section-title><ce:para id="p0200" view="all">We next sought to determine whether hepatocyte-like cells differentiated from FAP-specific iPS cells would indeed express TTR. Expression of TTR mRNA was detectable from D13 (<ce:cross-ref refid="f0020" id="cf0355">Fig. 4</ce:cross-ref>A<ce:float-anchor refid="f0020"/>). To confirm the presence of TTR protein, Western blotting of culture supernatant was performed with an anti-human TTR antibody. As <ce:cross-ref refid="f0020" id="cf0360">Fig. 4</ce:cross-ref>B shows, expression of TTR protein levels was confirmed in the concentrated D20 culture supernatant. The approximate concentration of TTR protein in the media of differentiated FAP-specific iPS cells was approximately 2.28<ce:hsp sp="0.25"/>μg/ml (<ce:cross-ref refid="f0020" id="cf0365">Fig. 4</ce:cross-ref>C). In addition, the PCR-RFLP method showed that hepatocyte-like cells differentiated from FAP-specific iPS cells indeed expressed ATTR Val30Met and wild-type TTR mRNA, similar to expression in the liver of the FAP patient from whom FAP-specific iPS cells were generated (<ce:cross-ref refid="f0025" id="cf0370">Fig. 5</ce:cross-ref>A<ce:float-anchor refid="f0025"/>). Moreover, LC-MS/MS analysis clearly showed that hepatocyte-like cells differentiated from FAP-specific iPS cells indeed expressed both ATTR Val30Met and wild-type TTR at protein level and the ratio of TTR protein to ATTR protein is approximately 1 to 1 in the D20 culture supernatant (<ce:cross-ref refid="f0025" id="cf0375">Fig. 5</ce:cross-ref>B). Other FAP-specific iPS cell lines also expressed both ATTR Val30Met and wild-type TTR at protein level in the culture supernatant (data not shown).</ce:para></ce:section></ce:section><ce:section id="s0020" view="all"><ce:section-title id="st0040">Discussion</ce:section-title><ce:para id="p0205" view="all">In the present study, we generated iPS cells from patients with FAP ATTR Val30Met by introducing four reprogramming factors (Oct3/4, Sox2, Klf 4, and c-Myc) into dermal fibroblasts via SeV vector infection. FAP-specific iPS cells had the potential to differentiate into hepatocyte-like cells, a major TTR-producing cell, and indeed expressed ATTR Val30Met and wild-type TTR protein. FAP-specific iPS cells demonstrated the possibility of serving as a pathological tool, which may contribute to elucidating the molecular pathogenesis of FAP and developing novel therapeutic strategies for FAP.</ce:para><ce:para id="p0210" view="all">Attempts to establish the experimental models of FAP (<ce:cross-refs refid="bb0065 bb0150 bb0055" id="cf0380">Buxbaum et al., 2003; Pokrzywa et al., 2007; Berg et al., 2009</ce:cross-refs>) have not been as successful as researchers would wish. It has been reported that transgenic mice overexpressing mutated TTR did not display signs of neuropathology (<ce:cross-ref refid="bb0065" id="cf0385">Buxbaum et al., 2003</ce:cross-ref>). It is still controversial whether the pathogenic mechanism of FAP in <ce:italic>Drosophila</ce:italic> model is in the same manner as human (<ce:cross-refs refid="bb0150 bb0055" id="cf0390">Pokrzywa et al., 2007; Berg et al., 2009</ce:cross-refs>). In addition, a review of previous studies about the molecular pathogenesis of FAP indicates that most of the studies investigated the pathologic effect of ATTR using non-mutant cells or an artificial high expression system (<ce:cross-refs refid="bb0195 bb0070 bb0170" id="cf0395">Sousa et al., 2000; Cardoso et al., 2008; Sato et al., 2007</ce:cross-refs>). Indeed, the neurodegeneration induced by ATTR or endoplasmic reticulum quality control of ATTR was studied with non-mutant mammalian cells transfected with the receptor for advanced glycation end products (<ce:cross-ref refid="bb0195" id="cf0400">Sousa et al., 2000</ce:cross-ref>) or wild-type TTR and ATTR (<ce:cross-ref refid="bb0170" id="cf0405">Sato et al., 2007</ce:cross-ref>). Because FAP is an autosomal-dominant hereditary disease and those systems did not utilize heterozygous ATTR mutant cell models, those systems do not fully represent the relevant processes in patients with FAP and are unsuitable for evaluation of therapy. The ratio of expression of TTR protein to ATTR protein varies among cells. As with iPS cells designed to be specific for other diseases, iPS cells generated from patients who were heterozygous for FAP are more useful for elucidating the pathogenesis of FAP: TTR and ATTR in heterozygous FAP form heterotetramers, which produce amyloid, and recombinant TTR forms a homotetramer, which is a totally different form of TTR in plasma and tissues. Generation of various FAP-specific iPS cells may help clarify the mechanism of the phenotypic variations among individuals with the same genotype (<ce:cross-ref refid="bb0120" id="cf0410">Kato-Motozaki et al., 2008</ce:cross-ref>) and the cellular and molecular pathogenesis. In this study, hepatocyte-like cells differentiated from FAP-specific iPS cells indeed secreted TTR and ATTR protein in the ratio of almost 1 to 1 as heterozygous ATTR mutant cells (<ce:cross-ref refid="f0025" id="cf0415">Fig. 5</ce:cross-ref>B). The amount of TTR protein was approximately 2.28<ce:hsp sp="0.25"/>μg/ml (<ce:cross-ref refid="f0020" id="cf0420">Fig. 4</ce:cross-ref>C), which is comparable with the previous result (0.2-2<ce:hsp sp="0.25"/>μg/ml) in functional hepatocyte-like cells differentiated from normal iPS cells (<ce:cross-ref refid="bb0215" id="cf0425">Sullivan et al., 2010</ce:cross-ref>), and exhibits 50 times higher than the previous result (0.034-0.057<ce:hsp sp="0.25"/>μg/ml) in human hepatocytes in primary culture (<ce:cross-ref refid="bb0240" id="cf0430">Wigmore et al., 1997</ce:cross-ref>). Moreover, differentiation of the same FAP-specific iPS cell line into various cells such as neurons and cardiomyocytes may aid understanding of the tissue selectivity of amyloidosis, which differs according to variants (<ce:cross-refs refid="bb0095 bb0175 bb0250" id="cf0435">Hammarstrom et al., 2003; Sekijima et al., 2003; Yamashita et al., 2005</ce:cross-refs>). Studies of other FAP-specific iPS cell lines generated from TTR variants other than the Val30Met mutation are currently in progress. FAP-specific iPS cells may also be used for screening novel drug candidates such as inhibitors of amyloid formation. Additional investigations are needed to evaluate the phenotype of FAP-specific iPS cells in greater detail and confirm the value of these cells as a novel experimental tool of FAP.</ce:para><ce:para id="p0215" view="all">In this study, we took full advantage of the special characteristics of this SeV vector to establish FAP-specific iPS cells. Because SeV vectors replicate only in the cytoplasm of infected cells and do not integrate into the host genome (<ce:cross-ref refid="bb0130" id="cf0440">Li et al., 2000</ce:cross-ref>), no risk of modifying the host genome exists. Using retrovirus or lentivirus vectors results in integration of viral transgenes into the host genome, which includes a risk of tumorigenicity (<ce:cross-refs refid="bb0105 bb0090" id="cf0445">Hussein et al., 2011; Gore et al., 2011</ce:cross-refs>). To solve this problem, plasmids (<ce:cross-ref refid="bb0140" id="cf0450">Okita et al., 2008</ce:cross-ref>), a Cre/loxP system (<ce:cross-ref refid="bb0190" id="cf0455">Soldner et al., 2009</ce:cross-ref>), adenoviruses (<ce:cross-ref refid="bb0200" id="cf0460">Stadtfeld et al., 2008</ce:cross-ref>), piggyback (<ce:cross-ref refid="bb0245" id="cf0465">Woltjen et al., 2009</ce:cross-ref>), a minicircle vector (<ce:cross-ref refid="bb0110" id="cf0470">Jia et al., 2010</ce:cross-ref>), and proteins (<ce:cross-ref refid="bb0260" id="cf0475">Zhou et al., 2009</ce:cross-ref>) have been developed. The risk of integration into the genome still remains, however, for DNA-type vectors (<ce:cross-ref refid="bb0100" id="cf0480">Harui et al., 1999</ce:cross-ref>), and those methods also demonstrated low induction efficiency. Thus, the SeV vector that we used is believed to have a significant advantage compared with available methods because of its safety, efficiency, and convenience. SeV vectors are slowly diluted and disappear during iPS cell division, and SeV vector-positive cells can be removed by means of an anti-SeV-HN antibody (<ce:cross-ref refid="bb0085" id="cf0485">Fusaki et al., 2009</ce:cross-ref>). Moreover, with the temperature-sensitive SeV vector used in this study, vectors, even if present, could easily be removed after the temperature shift treatment and would not be reactivated in iPS cells (<ce:cross-ref refid="bb0045" id="cf0490">Ban et al., 2011</ce:cross-ref>). FAP-specific iPS cells would thus be safe and may be a source for cell replacement therapy.</ce:para></ce:section><ce:section id="s0025" view="all"><ce:section-title id="st0045">Conclusions</ce:section-title><ce:para id="p0220" view="all">We successfully generated, for the first time, FAP-specific iPS cells. Such FAP-specific iPS cells may serve as valuable experimental tools to clarify the molecular pathogenesis of FAP, with potential value in cell therapy applications.</ce:para></ce:section></ce:sections><ce:acknowledgment id="ac0005" view="all"><ce:section-title id="st0050">Acknowledgments</ce:section-title><ce:para id="p0225" view="all">We thank Dr. Konen Obayashi for technical assistance and Mrs. Hiroko Katsura for her technical support during histopathologic investigations.</ce:para></ce:acknowledgment></body><tail view="all"><ce:bibliography id="bi0005" view="all"><ce:section-title id="st0055">References</ce:section-title><ce:bibliography-sec id="bs0005" view="all"><ce:bib-reference id="bb0005"><ce:label>Ando and Suhr, 1998</ce:label><sb:reference id="rf0005"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Ando</ce:surname></sb:author><sb:author><ce:given-name>O.B.</ce:given-name><ce:surname>Suhr</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP)</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Amyloid</sb:maintitle></sb:title><sb:volume-nr>5</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>288</sb:first-page><sb:last-page>300</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0010"><ce:label>Ando and Ueda, 2012</ce:label><sb:reference id="rf0010"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Ando</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Ueda</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Diagnosis and therapeutic approaches to transthyretin amyloidosis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Curr. Med. Chem.</sb:maintitle></sb:title><sb:volume-nr>19</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>2312</sb:first-page><sb:last-page>2323</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0015"><ce:label>Ando et al., 1993</ce:label><sb:reference id="rf0015"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Ando</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Araki</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Ando</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Transthyretin and familial amyloidotic polyneuropathy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Intern. Med.</sb:maintitle></sb:title><sb:volume-nr>32</sb:volume-nr></sb:series><sb:date>1993</sb:date></sb:issue><sb:pages><sb:first-page>920</sb:first-page><sb:last-page>922</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0020"><ce:label>Ando et al., 1995a</ce:label><sb:reference id="rf0020"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Ando</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Tanaka</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Nakazato</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Change in variant transthyretin levels in patients with familial amyloidotic polyneuropathy type I following liver transplantation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochem. Biophys. Res. Commun.</sb:maintitle></sb:title><sb:volume-nr>211</sb:volume-nr></sb:series><sb:date>1995</sb:date></sb:issue><sb:pages><sb:first-page>354</sb:first-page><sb:last-page>358</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0025"><ce:label>Ando et al., 1995b</ce:label><sb:reference id="rf0025"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Ando</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Tanaka</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Ando</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Effect of liver transplantation on autonomic dysfunction in familial amyloidotic polyneuropathy type I</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Lancet</sb:maintitle></sb:title><sb:volume-nr>345</sb:volume-nr></sb:series><sb:date>1995</sb:date></sb:issue><sb:pages><sb:first-page>195</sb:first-page><sb:last-page>196</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0030"><ce:label>Ando et al., 1997</ce:label><sb:reference id="rf0030"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Ando</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Ando</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Okamura</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Ocular manifestations of familial amyloidotic polyneuropathy type I: long-term follow up</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Br. J. Ophthalmol.</sb:maintitle></sb:title><sb:volume-nr>81</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>295</sb:first-page><sb:last-page>298</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0035"><ce:label>Ando et al., 2005</ce:label><sb:reference id="rf0035"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Ando</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Nakamura</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Araki</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Transthyretin-related familial amyloidotic polyneuropathy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Arch. Neurol.</sb:maintitle></sb:title><sb:volume-nr>62</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>1057</sb:first-page><sb:last-page>1062</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0040"><ce:label>Araki, 1984</ce:label><sb:reference id="rf0040"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Araki</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Type I, familial amyloidotic polyneuropathy (Japanese type)</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Dev.</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>1984</sb:date></sb:issue><sb:pages><sb:first-page>128</sb:first-page><sb:last-page>133</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0045"><ce:label>Ban et al., 2011</ce:label><sb:reference id="rf0045"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Ban</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Nishishita</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Fusaki</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle></sb:title><sb:volume-nr>108</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>14234</sb:first-page><sb:last-page>14239</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0050"><ce:label>Benson and Kincaid, 2007</ce:label><sb:reference id="rf0050"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.D.</ce:given-name><ce:surname>Benson</ce:surname></sb:author><sb:author><ce:given-name>J.C.</ce:given-name><ce:surname>Kincaid</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>The molecular biology and clinical features of amyloid neuropathy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Muscle Nerve</sb:maintitle></sb:title><sb:volume-nr>36</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>411</sb:first-page><sb:last-page>423</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0055"><ce:label>Berg et al., 2009</ce:label><sb:reference id="rf0055"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Berg</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Thor</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Hammarstrom</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Modeling familial amyloidotic polyneuropathy (transthyretin V30M) in <ce:italic>Drosophila melanogaster</ce:italic></sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurodegener. Dis.</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>127</sb:first-page><sb:last-page>138</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0060"><ce:label>Buxbaum and Reixach, 2009</ce:label><sb:reference id="rf0060"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.N.</ce:given-name><ce:surname>Buxbaum</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Reixach</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Transthyretin: the servant of many masters</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell. Mol. Life Sci.</sb:maintitle></sb:title><sb:volume-nr>66</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>3095</sb:first-page><sb:last-page>3101</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0065"><ce:label>Buxbaum et al., 2003</ce:label><sb:reference id="rf0065"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Buxbaum</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Tagoe</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Gallo</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>The pathogenesis of transthyretin tissue deposition: lessons from transgenic mice</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Amyloid</sb:maintitle></sb:title><sb:volume-nr>10</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>2</sb:first-page><sb:last-page>6</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0070"><ce:label>Cardoso et al., 2008</ce:label><sb:reference id="rf0070"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Cardoso</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Brito</ce:surname></sb:author><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Saraiva</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Extracellular matrix markers for disease progression and follow-up of therapies in familial amyloid polyneuropathy V30M TTR-related</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Dis. Markers</sb:maintitle></sb:title><sb:volume-nr>25</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>37</sb:first-page><sb:last-page>47</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0075"><ce:label>Dimos et al., 2008</ce:label><sb:reference id="rf0075"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.T.</ce:given-name><ce:surname>Dimos</ce:surname></sb:author><sb:author><ce:given-name>K.T.</ce:given-name><ce:surname>Rodolfa</ce:surname></sb:author><sb:author><ce:given-name>K.K.</ce:given-name><ce:surname>Niakan</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Science</sb:maintitle></sb:title><sb:volume-nr>321</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>1218</sb:first-page><sb:last-page>1221</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0080"><ce:label>Ebert et al., 2009</ce:label><sb:reference id="rf0080"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.D.</ce:given-name><ce:surname>Ebert</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Yu</ce:surname></sb:author><sb:author><ce:given-name>F.F.</ce:given-name><ce:surname>Rose</ce:surname><ce:suffix>Jr.</ce:suffix></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Induced pluripotent stem cells from a spinal muscular atrophy patient</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>457</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>277</sb:first-page><sb:last-page>280</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0085"><ce:label>Fusaki et al., 2009</ce:label><sb:reference id="rf0085"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Fusaki</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Ban</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Nishiyama</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Jpn. Acad. Ser. B</sb:maintitle></sb:title><sb:volume-nr>85</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>348</sb:first-page><sb:last-page>362</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0090"><ce:label>Gore et al., 2011</ce:label><sb:reference id="rf0090"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Gore</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Li</ce:surname></sb:author><sb:author><ce:given-name>H.L.</ce:given-name><ce:surname>Fung</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Somatic coding mutations in human induced pluripotent stem cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>471</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>63</sb:first-page><sb:last-page>67</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0095"><ce:label>Hammarstrom et al., 2003</ce:label><sb:reference id="rf0095"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Hammarstrom</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Sekijima</ce:surname></sb:author><sb:author><ce:given-name>J.T.</ce:given-name><ce:surname>White</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochemistry</sb:maintitle></sb:title><sb:volume-nr>42</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>6656</sb:first-page><sb:last-page>6663</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0100"><ce:label>Harui et al., 1999</ce:label><sb:reference id="rf0100"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Harui</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Suzuki</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Kochanek</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Frequency and stability of chromosomal integration of adenovirus vectors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Virol.</sb:maintitle></sb:title><sb:volume-nr>73</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>6141</sb:first-page><sb:last-page>6146</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0105"><ce:label>Hussein et al., 2011</ce:label><sb:reference id="rf0105"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.M.</ce:given-name><ce:surname>Hussein</ce:surname></sb:author><sb:author><ce:given-name>N.N.</ce:given-name><ce:surname>Batada</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Vuoristo</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Copy number variation and selection during reprogramming to pluripotency</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>471</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>58</sb:first-page><sb:last-page>62</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0110"><ce:label>Jia et al., 2010</ce:label><sb:reference id="rf0110"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Jia</ce:surname></sb:author><sb:author><ce:given-name>K.D.</ce:given-name><ce:surname>Wilson</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Sun</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>A nonviral minicircle vector for deriving human iPS cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nat. Methods</sb:maintitle></sb:title><sb:volume-nr>7</sb:volume-nr></sb:series><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>197</sb:first-page><sb:last-page>199</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0115"><ce:label>Kanai et al., 1968</ce:label><sb:reference id="rf0115"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Kanai</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Raz</ce:surname></sb:author><sb:author><ce:given-name>D.S.</ce:given-name><ce:surname>Goodman</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Retinol-binding protein: the transport protein for vitamin A in human plasma</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Clin. Invest.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:date>1968</sb:date></sb:issue><sb:pages><sb:first-page>2025</sb:first-page><sb:last-page>2044</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0120"><ce:label>Kato-Motozaki et al., 2008</ce:label><sb:reference id="rf0120"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Kato-Motozaki</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Ono</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Shima</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Epidemiology of familial amyloid polyneuropathy in Japan: identification of a novel endemic focus</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurol. Sci.</sb:maintitle></sb:title><sb:volume-nr>270</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>133</sb:first-page><sb:last-page>140</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0125"><ce:label>Kawaji et al., 2005</ce:label><sb:reference id="rf0125"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Kawaji</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Ando</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Nakamura</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Transthyretin synthesis in rabbit ciliary pigment epithelium</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Exp. Eye Res.</sb:maintitle></sb:title><sb:volume-nr>81</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>306</sb:first-page><sb:last-page>312</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0130"><ce:label>Li et al., 2000</ce:label><sb:reference id="rf0130"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>H.O.</ce:given-name><ce:surname>Li</ce:surname></sb:author><sb:author><ce:given-name>Y.F.</ce:given-name><ce:surname>Zhu</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Asakawa</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Virol.</sb:maintitle></sb:title><sb:volume-nr>74</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>6564</sb:first-page><sb:last-page>6569</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0135"><ce:label>Maehr et al., 2009</ce:label><sb:reference id="rf0135"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Maehr</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Chen</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Snitow</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Generation of pluripotent stem cells from patients with type 1 diabetes</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle></sb:title><sb:volume-nr>106</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>15768</sb:first-page><sb:last-page>15773</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0140"><ce:label>Okita et al., 2008</ce:label><sb:reference id="rf0140"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Okita</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Nakagawa</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Hyenjong</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Generation of mouse induced pluripotent stem cells without viral vectors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Science</sb:maintitle></sb:title><sb:volume-nr>322</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>949</sb:first-page><sb:last-page>953</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0145"><ce:label>Ong et al., 1994</ce:label><sb:reference id="rf0145"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>D.E.</ce:given-name><ce:surname>Ong</ce:surname></sb:author><sb:author><ce:given-name>J.T.</ce:given-name><ce:surname>Davis</ce:surname></sb:author><sb:author><ce:given-name>W.T.</ce:given-name><ce:surname>O'Day</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Synthesis and secretion of retinol-binding protein and transthyretin by cultured retinal pigment epithelium</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Biochemistry</sb:maintitle></sb:title><sb:volume-nr>33</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>1835</sb:first-page><sb:last-page>1842</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0150"><ce:label>Pokrzywa et al., 2007</ce:label><sb:reference id="rf0150"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Pokrzywa</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Dacklin</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Hultmark</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Misfolded transthyretin causes behavioral changes in a <ce:italic>Drosophila</ce:italic> model for transthyretin-associated amyloidosis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Eur. J. Neurosci.</sb:maintitle></sb:title><sb:volume-nr>26</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>913</sb:first-page><sb:last-page>924</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0155"><ce:label>Raya et al., 2009</ce:label><sb:reference id="rf0155"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Raya</ce:surname></sb:author><sb:author><ce:given-name>I.</ce:given-name><ce:surname>Rodriguez-Piza</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Guenechea</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>460</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>53</sb:first-page><sb:last-page>59</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0160"><ce:label>Saha and Jaenisch, 2009</ce:label><sb:reference id="rf0160"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Saha</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Jaenisch</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Technical challenges in using human induced pluripotent stem cells to model disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell Stem Cell</sb:maintitle></sb:title><sb:volume-nr>5</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>584</sb:first-page><sb:last-page>595</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0165"><ce:label>Saraiva et al., 1983</ce:label><sb:reference id="rf0165"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.J.</ce:given-name><ce:surname>Saraiva</ce:surname></sb:author><sb:author><ce:given-name>P.P.</ce:given-name><ce:surname>Costa</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Birken</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Presence of an abnormal transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Trans. Assoc. Am. Physicians</sb:maintitle></sb:title><sb:volume-nr>96</sb:volume-nr></sb:series><sb:date>1983</sb:date></sb:issue><sb:pages><sb:first-page>261</sb:first-page><sb:last-page>270</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0170"><ce:label>Sato et al., 2007</ce:label><sb:reference id="rf0170"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Sato</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Susuki</ce:surname></sb:author><sb:author><ce:given-name>M.A.</ce:given-name><ce:surname>Suico</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Endoplasmic reticulum quality control regulates the fate of transthyretin variants in the cell</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>EMBO J.</sb:maintitle></sb:title><sb:volume-nr>26</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>2501</sb:first-page><sb:last-page>2512</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0175"><ce:label>Sekijima et al., 2003</ce:label><sb:reference id="rf0175"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Sekijima</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Hammarstrom</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Matsumura</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Lab. Invest.</sb:maintitle></sb:title><sb:volume-nr>83</sb:volume-nr></sb:series><sb:date>2003</sb:date></sb:issue><sb:pages><sb:first-page>409</sb:first-page><sb:last-page>417</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0180"><ce:label>Shiraki et al., 2008</ce:label><sb:reference id="rf0180"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Shiraki</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Umeda</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Sakashita</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Differentiation of mouse and human embryonic stem cells into hepatic lineages</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Genes Cells</sb:maintitle></sb:title><sb:volume-nr>13</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>731</sb:first-page><sb:last-page>746</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0185"><ce:label>Shiraki et al., 2011</ce:label><sb:reference id="rf0185"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Shiraki</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Yamazoe</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Qin</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Efficient differentiation of embryonic stem cells into hepatic cells in vitro using a feeder-free basement membrane substratum</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>PLoS One</sb:maintitle></sb:title><sb:volume-nr>6</sb:volume-nr></sb:series><sb:date>2011</sb:date></sb:issue><sb:pages><sb:first-page>e24228</sb:first-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0190"><ce:label>Soldner et al., 2009</ce:label><sb:reference id="rf0190"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>F.</ce:given-name><ce:surname>Soldner</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Hockemeyer</ce:surname></sb:author><sb:author><ce:given-name>C.</ce:given-name><ce:surname>Beard</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell</sb:maintitle></sb:title><sb:volume-nr>136</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>964</sb:first-page><sb:last-page>977</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0195"><ce:label>Sousa et al., 2000</ce:label><sb:reference id="rf0195"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.M.</ce:given-name><ce:surname>Sousa</ce:surname></sb:author><sb:author><ce:given-name>S.D.</ce:given-name><ce:surname>Yan</ce:surname></sb:author><sb:author><ce:given-name>D.</ce:given-name><ce:surname>Stern</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor κB (NF-κB) activation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Lab. Invest.</sb:maintitle></sb:title><sb:volume-nr>80</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>1101</sb:first-page><sb:last-page>1110</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0200"><ce:label>Stadtfeld et al., 2008</ce:label><sb:reference id="rf0200"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Stadtfeld</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Nagaya</ce:surname></sb:author><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Utikal</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Induced pluripotent stem cells generated without viral integration</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Science</sb:maintitle></sb:title><sb:volume-nr>322</sb:volume-nr></sb:series><sb:date>2008</sb:date></sb:issue><sb:pages><sb:first-page>945</sb:first-page><sb:last-page>949</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0205"><ce:label>Sueyoshi et al., 2012</ce:label><sb:reference id="rf0205"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Sueyoshi</ce:surname></sb:author><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Jono</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Shinriki</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Therapeutic approaches targeting midkine suppress tumor growth and lung metastasis in osteosarcoma</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cancer Lett.</sb:maintitle></sb:title><sb:volume-nr>316</sb:volume-nr></sb:series><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>23</sb:first-page><sb:last-page>30</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0210"><ce:label>Suhr et al., 1995</ce:label><sb:reference id="rf0210"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>O.B.</ce:given-name><ce:surname>Suhr</ce:surname></sb:author><sb:author><ce:given-name>G.</ce:given-name><ce:surname>Holmgren</ce:surname></sb:author><sb:author><ce:given-name>L.</ce:given-name><ce:surname>Steen</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Transplantation</sb:maintitle></sb:title><sb:volume-nr>60</sb:volume-nr></sb:series><sb:date>1995</sb:date></sb:issue><sb:pages><sb:first-page>933</sb:first-page><sb:last-page>938</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0215"><ce:label>Sullivan et al., 2010</ce:label><sb:reference id="rf0215"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G.J.</ce:given-name><ce:surname>Sullivan</ce:surname></sb:author><sb:author><ce:given-name>D.C.</ce:given-name><ce:surname>Hay</ce:surname></sb:author><sb:author><ce:given-name>I.H.</ce:given-name><ce:surname>Park</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Generation of functional human hepatic endoderm from human induced pluripotent stem cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Hepatology</sb:maintitle></sb:title><sb:volume-nr>51</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>2010</sb:date></sb:issue><sb:pages><sb:first-page>329</sb:first-page><sb:last-page>335</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0220"><ce:label>Takahashi and Yamanaka, 2006</ce:label><sb:reference id="rf0220"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Takahashi</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Yamanaka</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell</sb:maintitle></sb:title><sb:volume-nr>126</sb:volume-nr></sb:series><sb:date>2006</sb:date></sb:issue><sb:pages><sb:first-page>663</sb:first-page><sb:last-page>676</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0225"><ce:label>Takahashi et al., 2007</ce:label><sb:reference id="rf0225"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Takahashi</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Tanabe</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Ohnuki</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Induction of pluripotent stem cells from adult human fibroblasts by defined factors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell</sb:maintitle></sb:title><sb:volume-nr>131</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>861</sb:first-page><sb:last-page>872</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0230"><ce:label>Ueda et al., 2009</ce:label><sb:reference id="rf0230"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Ueda</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Misumi</ce:surname></sb:author><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Mizuguchi</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin. Chem.</sb:maintitle></sb:title><sb:volume-nr>55</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>1223</sb:first-page><sb:last-page>1227</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0235"><ce:label>Westermark et al., 2002</ce:label><sb:reference id="rf0235"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Westermark</ce:surname></sb:author><sb:author><ce:given-name>M.D.</ce:given-name><ce:surname>Benson</ce:surname></sb:author><sb:author><ce:given-name>J.N.</ce:given-name><ce:surname>Buxbaum</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Amyloid fibril protein nomenclature - 2002</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Amyloid</sb:maintitle></sb:title><sb:volume-nr>9</sb:volume-nr></sb:series><sb:date>2002</sb:date></sb:issue><sb:pages><sb:first-page>197</sb:first-page><sb:last-page>200</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0240"><ce:label>Wigmore et al., 1997</ce:label><sb:reference id="rf0240"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S.J.</ce:given-name><ce:surname>Wigmore</ce:surname></sb:author><sb:author><ce:given-name>K.C.</ce:given-name><ce:surname>Fearon</ce:surname></sb:author><sb:author><ce:given-name>J.A.</ce:given-name><ce:surname>Ross</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Modulation of human hepatocyte acute phase protein production in vitro by n<ce:hsp sp="0.10"/>-<ce:hsp sp="0.10"/>3 and n<ce:hsp sp="0.10"/>-<ce:hsp sp="0.10"/>6 polyunsaturated fatty acids</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Surg.</sb:maintitle></sb:title><sb:volume-nr>225</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>103</sb:first-page><sb:last-page>111</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0245"><ce:label>Woltjen et al., 2009</ce:label><sb:reference id="rf0245"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Woltjen</ce:surname></sb:author><sb:author><ce:given-name>I.P.</ce:given-name><ce:surname>Michael</ce:surname></sb:author><sb:author><ce:given-name>P.</ce:given-name><ce:surname>Mohseni</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Nature</sb:maintitle></sb:title><sb:volume-nr>458</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>766</sb:first-page><sb:last-page>770</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0250"><ce:label>Yamashita et al., 2005</ce:label><sb:reference id="rf0250"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Yamashita</ce:surname></sb:author><sb:author><ce:given-name>Y.</ce:given-name><ce:surname>Ando</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Katsuragi</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Muscular amyloid angiopathy with amyloidogenic transthyretin Ser50Ile and Tyr114Cys</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Muscle Nerve</sb:maintitle></sb:title><sb:volume-nr>31</sb:volume-nr></sb:series><sb:date>2005</sb:date></sb:issue><sb:pages><sb:first-page>41</sb:first-page><sb:last-page>45</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0255"><ce:label>Yu et al., 2007</ce:label><sb:reference id="rf0255"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>J.</ce:given-name><ce:surname>Yu</ce:surname></sb:author><sb:author><ce:given-name>M.A.</ce:given-name><ce:surname>Vodyanik</ce:surname></sb:author><sb:author><ce:given-name>K.</ce:given-name><ce:surname>Smuga-Otto</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Induced pluripotent stem cell lines derived from human somatic cells</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Science</sb:maintitle></sb:title><sb:volume-nr>318</sb:volume-nr></sb:series><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>1917</sb:first-page><sb:last-page>1920</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bb0260"><ce:label>Zhou et al., 2009</ce:label><sb:reference id="rf0260"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>H.</ce:given-name><ce:surname>Zhou</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Wu</ce:surname></sb:author><sb:author><ce:given-name>J.Y.</ce:given-name><ce:surname>Joo</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Generation of induced pluripotent stem cells using recombinant proteins</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Cell Stem Cell</sb:maintitle></sb:title><sb:volume-nr>4</sb:volume-nr></sb:series><sb:date>2009</sb:date></sb:issue><sb:pages><sb:first-page>381</sb:first-page><sb:last-page>384</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article></xocs:serial-item></xocs:doc>
